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Abstract 
The inability of articular cartilage to heal after damage or disease has motivated 
investigation of novel cartilage tissue engineering technologies. The objective of this thesis was 
to advance the use of self-assembling peptide hydrogel scaffolds for cartilage repair by 
encapsulating bone-marrow-stromal cells (BMSCs) and incorporating chondrogenic cues to 
stimulate differentiation and neotissue production.  
To test the hypothesis that self-assembling peptide hydrogels provide cues which enhance 
the chondrogenic differentiation of BMSCs, a technique for rapid, high-viability BMSC 
encapsulation was developed. BMSCs were cultured in two peptide hydrogel sequences and 
compared to agarose hydrogels. BMSCs in all three hydrogels underwent TGF-β1-mediated 
chondrogenesis as demonstrated by comparable gene expression and ECM biosynthesis. Cell 
proliferation occurred only in the peptide hydrogels, not in agarose, resulting in higher sulfated-
glycosaminoglycan content and more spatially uniform proteoglycan and type II collagen 
deposition. These data showed that self-assembling peptide hydrogels enhance chondrogenesis 
compared to agarose. 
To evaluate the capacity for BMSCs from young and adult equine donors to produce 
cartilage-like ECM, neotissue formation was compared to that for animal-matched primary 
chondrocytes. Young chondrocytes stimulated by TGF-β1 accumulated ECM with higher 
sulfated-glycosaminoglycan content than adult chondrocytes and BMSCs of either age. BMSCs 
produced neotissue with higher dynamic stiffness than young chondrocytes. Measurement of 
aggrecan core-protein and chondroitin-sulfate length by atomic-force microscopy revealed 
BMSCs produce longer core protein and chondroitin-sulfate, and fewer catabolic-cleavage 
products than chondrocytes. Therefore, BMSC-produced aggrecan appears to have a younger 
phenotype than chondrocyte-produced aggrecan. These advantages make BMSCs a potentially 
superior cell source for peptide-hydrogel-based cartilage repair. 
To deliver TGF-β1 to BMSCs via a bioactive scaffold, BMSCs were encapsulated in 
peptide hydrogels with both tethered and adsorbed TGF-β1 and cultured in TGF-β1-free medium. 
Chondrogenesis was compared to that of unmodified peptide hydrogels with medium-delivered 
TGF-β1. Adsorbed-TGF-β1 peptide hydrogels stimulated chondrogenesis of BMSCs as 
demonstrated by cell proliferation and cartilage-like ECM accumulation, while tethered TGF-β1 
was not different from TGF-β1-free controls. TGF-β1 adsorbed to self-assembling peptide 
hydrogels can stimulate BMSC chondrogenesis. 
BMSC-seeded self-assembling peptide hydrogels, modified for controlled delivery of 
pro-chondrogenic factors, generate cartilage-like neotissue and are compatible with a single-
surgery, autologous therapy for cartilage repair. 
Thesis Supervisor: Alan J. Grodzinsky, Prof. of Biological, Electrical, Mechanical Engineering 
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1.1 Cartilage Injury and Disease 
The high prevalence of joint injury, subsequent osteoarthritis (OA), and the 
frequent disability that follows1-4 highlight the urgency for finding treatments that can 
repair articular cartilage damage, an irreversible step in disease progression. Recent 
studies have shown that joint injuries, including partial and full-thickness fractures of the 
articular cartilage surface, joint derangement, and tears of the meniscus and ligaments, 
can lead to the early onset of OA. Injuries during adolescence and young adulthood 
increase the risk of OA more than 2-fold from 6% in uninjured individuals to 13.9% in 
those with injuries3. In addition, radiographic evidence of OA was found in 80% of 
athletes 14 years after ligament tear injury, irrespective of the treatment received4. 
The degenerative changes of OA present a difficult challenge. Often the disease 
begins attacking joints long before pain and disability become symptomatic, leading to 
joint tissue damage2. Tissue degradation caused by OA includes weakened muscles and 
tendons, fissured and torn meniscus, osteophyte formation, inflamed synovium, and 
fissured, torn and destroyed cartilage2. Cartilage degradation is particularly critical as it is 
the major weight-bearing tissue within the joint and lacks the capacity for self-repair, 
making damage to it irreversible and resulting in approximately one million joint 
replacements per annum in the US and Europe combined2. Thus, while the development 
of treatments for OA will undoubtedly have to address the range of pathophysiological 
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processes involved in the disease2,5, it is likely that strategies which aim to halt OA 
progression will require a complementary strategy for cartilage repair and regeneration. 
 
1.2 Cartilage Repair 
The need to repair damage motivates the significant effort and resources invested 
in developing cartilage replacement techniques. Surgical procedures in clinical use for 
repairing cartilage provide symptomatic relief of joint pain, but result in the formation of 
predominantly fibrous tissue and fibrocartilage with reduced mechanical properties and 
limited long-term durability6. Microfracture is a minimally invasive procedure consisting 
of drilling holes in the subchondral bone plate at the defect site, inducing therapeutic 
bleeding and subsequent clot formation. The resulting repair provides good short-term 
improvements, but deterioration begins 18 months after surgery7. Osteochondral 
autografting or mosaicplasty is an approach to cartilage defect repair involving 
transplantation of grafts of cartilage cores with similar characteristics to the surrounding 
tissue. Significant complications to this procedure exist however, including surface 
discontinuity, unmatched thickness of donor and recipient cartilage, and weak 
fibrocartilage grouting. Coupled with the inherent donor-site morbidity, these issues raise 
significant questions about the long-term benefits for this procedure6. 
Autologous chondrocyte implantation (ACI) is an alternative approach to 
cartilage repair utilizing ex vivo expanded chondrocytes. Cartilage slices are obtained 
from a minor load-bearing area of the injured joint and chondrocytes are isolated and 
expanded in the laboratory. These chondrocytes are then injected into the joint in a 
second surgical procedure in which they are retained in the defect by suturing a periosteal 
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flap to the surrounding cartilage8. Advantages over mosaicplasty include a smaller donor 
site requirement due to the ex vivo expansion of chondrocytes and the flexibility to 
completely fill irregular defects. However, chondrocytes are known to dedifferentiate and 
lose the ability to produce cartilage ECM components during monolayer expansion9. 
Furthermore, a direct comparison of ACI with microfracture in a randomized trial 
showed no significant differences between the two treatments at either two or five 
years10,11. 
 
1.3 Cartilage Tissue Engineering 
Cartilage tissue engineering has the potential to regenerate mature hyaline 
cartilage for repair in cases of injury or disease. Consisting of a cell source, a three-
dimensional scaffold and the appropriate cues for tissue formation, tissue engineering 
strategies for cartilage repair were initially based on ACI and utilized autologous 
chondrocytes seeded into absorbable scaffolds12. Further improvements included the use 
of allogeneic cells, chondro-inductive matrix, and ex vivo mechanical stimulation with 
the goals of homogeneous defect fill, a single-surgery treatment, elimination of suturing, 
and improved material properties12. Despite these efforts, no technique has yet succeeded 
in generating fully-functional cartilage repair13. 
Recently, bone marrow derived stromal cells (BMSCs) have been isolated and 
shown to have the capacity to differentiate into many lineages, including bone, adipose, 
muscle, and cartilage14,15.  Because bone marrow samples can be harvested via minimally 
invasive techniques, these cells eliminate the need for two surgical procedures, which 
were necessary with ACI. These cells have the ability to be expanded rapidly in 
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monolayer culture and then induced to differentiate into a chondrocyte-like phenotype, 
either by encapsulating them in three-dimensional culture, administering the appropriate 
growth factors16, subjecting them to mechanical loading17, or a combination of these 
stimuli.  It has been shown that type II collagen hydrogels have the potential to induce 
and maintain BMSC chondrogenesis18, especially when stimulated by transforming 
growth factor β1 (TGF-β1).  In addition, through the combined use of insulin-like growth 
factor I and TGF-β1, it is possible to achieve effective proliferation and chondrogenesis 
of human BMSCs derived from aged individuals (>50 years old)19.  Due to the expense 
of long-term growth factor treatment, there may be significant advantages to delivering 
these factors via functionalized scaffolds, which sustain signaling via growth factor 
tethering20. 
Self-assembling peptide hydrogels, a new class of biomaterials, have recently 
been discovered and been shown to have many applications in biotechnology21,22.  When 
used as a 3-D environment for cell-culture, these materials allow for study and 
manipulation of cells that is not possible in vivo23 and may be used as novel scaffolds for 
tissue engineering24.  Injection of cell-free peptides into the myocardium can lead to the 
recruitment of vascular cells to the resulting microenvironment, and promote the survival 
of endogenous precursor cells25.  Self-assembling peptide hydrogels have been applied in 
cartilage repair strategies, and been shown to stimulate ECM production and cell division 
in primary chondrocyte-laden constructs for cartilage tissue repair26.  BMSC-laden 
peptide constructs achieve significant matrix accumulation and mechanical properties 
over a six-week time course27.  In addition, bone-marrow derived BMSCs showed 4-fold 
higher GAG accumulation and nearly 8-fold higher biosynthesis rates when seeded in 
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peptide hydrogels as compared to agarose hydrogels28, suggesting the potential for 
BMSC chondrogenesis and ECM production when encapsulated in peptide hydrogels. 
 
1.4 Thesis Outline 
The objective of this thesis was to advance the use of self-assembling peptide 
hydrogel scaffolds for cartilage tissue repair by encapsulating BMSCs and incorporating 
chondrogenic cues to stimulate differentiation and neotissue production. 
Studies described in chapter 2 investigated self-assembling peptide hydrogel 
scaffolds to determine if they provide cues that enhance the chondrogenic differentiation 
of BMSCs. Sequence specific effects of two different peptide hydrogels, KLD12 
(KLDL)3 and RAD16 (RADA)4, on BMSC chondrogenesis were evaluated and compared 
to a reference system of BMSCs encapsulated in agarose hydrogels. 
Studies described in chapter 3 explored the effects of cell type and age on 
chondrogenic potential by determining the capacity for BMSCs and chondrocytes from 
young and adult equine donors to produce a cartilage-like ECM. Neotissue biochemical 
and biomechanical properties are used to characterize chondrogenesis as well as 
molecular properties of neotissue extracted aggrecan. 
In studies described in chapter 4, self-assembling peptide hydrogels were 
modified to deliver TGF-β1, a prochondrogenic growth factor, to encapsulated BMSCs 
via biotin-streptavidin tethering and growth factor adsorption. Growth factor retention 
within acellular peptide hydrogels was characterized and chondrogenesis of BMSCs 
encapsulated within growth-factor modified peptide was evaluated. TGF-β1 signaling in 
modified-peptide hydrogels via the Smad 2/3 intracellular pathway was also assessed. 
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Finally, in Chapter 5 the main findings and conclusions are discussed and new 
questions motivated by this thesis are explored. 
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The objective of this study was to test the hypothesis that self-assembling peptide 
hydrogel scaffolds provide cues which enhance the chondrogenic differentiation of bone 
marrow stromal cells (BMSCs).  BMSCs were encapsulated within two unique peptide 
hydrogel sequences and chondrogenesis was compared to that in agarose hydrogels. 
Unique cell morphologies were observed for BMSCs in each peptide hydrogel sequence, 
with extensive cell-cell contact present for both, whereas BMSCs in agarose remained 
rounded over 21 days in culture. Differences in cell morphology within the two peptide 
scaffolds may be related to sequence-specific cell adhesion. BMSCs in all three 
hydrogels underwent TGF-β1-mediated chondrogenesis as demonstrated by comparable 
gene expression and biosynthesis of ECM molecules. Expression of an osteogenic marker 
was unchanged and an adipogenic marker was suppressed by TGF-β1 in all hydrogels. 
Cell proliferation occurred only in the peptide hydrogels, not in agarose; resulting in 
higher glycosaminoglycan content and more spatially uniform proteoglycan and collagen 
type II deposition. The G1-positive aggrecan produced in peptide hydrogels was 
predominantly the full-length species, whereas that in agarose appeared to be 
predominantly the aggrecanase product G1-NITEGE. Taken together, this study showed 
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self-assembling peptide hydrogels enhance chondrogenesis compared to agarose as 
shown by ECM production, DNA content and aggrecan molecular structure. 
 
2.1 Introduction 
Bone marrow stromal cells (BMSCs) have been widely used as a cell source for 
tissue-engineering strategies aimed at resurfacing articular cartilage14,16,29. Significant 
progress has been made demonstrating the potential for BMSCs to undergo 
chondrogenesis and produce a cartilage-like extracellular matrix (ECM) when 
encapsulated in a variety of three-dimensional scaffolds including agarose30,31, alginate32, 
collagen type I33,34, gelatin/albumin35, and silk-elastin36, but challenges in the use of 
BMSCs in the repair of cartilage defects still remain13,37. Improvements in BMSC 
chondrogenesis and eventual clinical use appear to require optimization of many factors. 
Among these is the current belief that the scaffold must provide the appropriate cell 
microenvironment and differentiation cues38. An ideal cartilage tissue engineering 
scaffold should be biocompatible, allow for cell adhesion, migration, and proliferation, 
and have sufficient porosity and hydration to permit nutrient and waste product flow. It 
should also stimulate production of an in vivo-like cartilage matrix with the appropriate 
cell-dependent turnover pathways. Finally it should be able to fill irregular defects, 
integrate effectively with the native recipient tissue, and degrade with the appropriate 
resorption kinetics13,38. 
Self-assembling peptides are a relatively new class of molecules that have the 
capacity to form stable hydrogels and encapsulate viable cells for potential therapeutic 
applications22,39,40. One type of these peptides consists of short oligomers of alternating 
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hydrophilic and hydrophobic residues that trigger self-assembly upon exposure to 
physiologic pH and ionic strength22. These peptides are completely synthetic, which 
avoids the potential pathogenicity of animal-derived materials24 and because of their 
rapid self-assembly, they are useful for cell encapsulation in both in vitro and in vivo 
applications. Various sequences have been used as tissue engineering scaffolds including 
KLD12 ([KLDL]3) for cartilage26, RAD16-I ([RADA]4) for cartilage41 and liver42,43, and 
RAD16-II ([RARADADA]2) for cardiovascular20 tissue repair. In addition, a recent study 
has shown that equine BMSCs encapsulated in KLD12 peptide hydrogels can undergo in 
vitro chondrogenesis28. 
A successful cartilage repair therapy ultimately must generate a tissue with 
comparable ECM biochemistry and biomechanics to native tissue. Also, it will likely 
require that cues are provided to guide the BMSCs to closely mimic the temporal 
sequence of genetic, biochemical, and biophysical events in native chondrogenesis44,45. It 
is thus important that a detailed analysis of chondrogenesis for any cell-based therapy be 
performed in vitro as an assessment of its potential repair capacity in vivo. Measurements 
include chondrogenic gene expression at initial and subsequent timepoints46, 
characterization of early time-dependent changes in cell morphology33, quantification of 
cell content32, production and analysis of secreted ECM components31,47, and assessment 
of both anabolic and catabolic ECM processing48. Previous reports have used these 
analytical techniques to demonstrate how altering the cell microenvironment impacts 
BMSC chondrogenesis and neo-tissue formation32,46,49. 
The objective of this study was to evaluate whether two different peptide 
hydrogels, KLD12 and RAD16-I, provided sequence-specific cues which enhanced 
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transforming growth factor-β1 (TGF-β1) stimulated chondrogenesis of BMSCs as 
compared to agarose hydrogel culture. Agarose was chosen as a reference because of its 
extensive use to study chondrocyte biology in three-dimensional culture9,50,51 and to 
evaluate progenitor cell differentiation28,30,41,48. Real-time RT-PCR was used to 
quantitatively assess expression of genes important for differentiation and ECM 
production. Neo-tissue cell content was measured by construct DNA content. The 
synthesis rate and accumulation of newly secreted ECM were also assessed 
biochemically. Changes in cytoskeleton morphology were characterized via F-actin 
imaging, and immunohistochemistry and immunoblotting were used to determine the 
type of ECM molecules and catabolic products. Time-points for this study were chosen 
from 1-21 days of culture with the goal of understanding how peptide sequence impacts 
the initial stages of chondrogenesis. 
 
2.2 Materials and Methods 
Materials 
Low-melting-point agarose was from Invitrogen, (Carlsbad, CA). KLD12 peptide 
with the sequence AcN-(KLDL)3-CNH2 was synthesized by the MIT Biopolymers 
Laboratory (Cambridge, MA) using an ABI Model 433A peptide synthesizer with FMOC 
protection. RAD16-I peptide with the sequence (RADA)4 was a gift of Puramatrix from 
3DM, Inc. (Cambridge, MA). All other materials were purchased from the suppliers 
noted below. 
 
 
 19
Cell isolation and expansion 
BMSCs were isolated as described previously31. Briefly, bone marrow was 
harvested aseptically from three newborn bovine calves (Research 87, Marlborough, MA). 
Following centrifugation at 1000g for 15 min, the cell pellet was washed in PBS and 
plated at 1x106 mononuclear cells/cm2 in expansion medium (EM) consisting of low 
glucose DMEM plus 10% ES-FBS (Invitrogen), HEPES, and PSA (100 U/mL penicillin, 
100 µg/mL streptomycin, and 250 ng/mL amphotericin) plus 1 ng/mL bFGF (R&D 
Systems, Minneapolis, MN). Non-adherent cells were removed by a medium change after 
48 hours, and colonies were harvested with 0.05% trypsin/1mM EDTA (Invitrogen) after 
approximately 7 days (passage 0) and cryopreserved. Six days prior to peptide hydrogel 
encapsulation, cells were thawed and plated at 6x103/cm2 in EM plus 5 ng/mL bFGF.  
After 3 days, cells were detached at ~3x104 cells/cm2 (passage 1) and reseeded at 
6x103/cm2.  This expansion was repeated during the subsequent 3 days after which cells 
were detached for encapsulation in 3D peptide hydrogels. 
 
Hydrogel Encapsulation and Culture 
BMSCs were encapsulated in either 2% (w/v) low-melting point agarose, 0.35% 
(w/v) KLD12 peptide, or 0.5% (w/v) RAD16-I peptide at a concentration of 107 cells/mL. 
The different concentrations for the self-assembling peptides were chosen so that initially 
the hydrogels would have similar mechanical characteristics52,53, and 2% agarose was 
selected for comparison with previously published studies30,31,41,48. Hydrogel disks with 
50µL initial volume were cast in neutral-buffered, acellular agarose molds to initiate self 
assembly (Fig. 2.1) and cultured in high glucose DMEM (Invitrogen) supplemented with 
1% ITS+1 (Sigma-Aldrich, St. Louis, MO), 0.1 µM dexamethasone (Sigma-Aldrich), 
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37.5 µg/mL ascorbate-2-phosphate (Wako Chemicals, Richmond, VA), PSA, HEPES, 
Proline, and NEAA, with (+TGF-β1) or without (Cntl) 10 ng/mL recombinant human 
TGF-β1 (R&D Systems), with medium changes every 2-3 days. 
 
Histology and Immunohistochemistry 
Hydrogels were fixed in 10% neutral-buffered formalin overnight at 4°C. For F-
actin staining, 3D hydrogel samples were sliced to ~700 µm thick, and permeabilized in 
PBS with 0.1% Triton-X at room temperature for 1 hour. Samples were washed 2-3 times 
with PBS and stained for 1 hour at room temperature with Texas Red conjugated 
phalloidin to show F-actin fibers and Hoechst dye to visualize cell nuclei. Samples were 
washed 2-3 times with PBS and imaged with a Nikon Eclipse fluorescent microscope or 
with a Zeiss LSM510 confocal microscope. For ECM staining, formalin fixed hydrogels 
were embedded in paraffin and sliced to 7 µm using a sledge-microtome (Leitz, Wetzlar, 
Germany). Sections were deparaffinized, treated with 0.1% pepsin for 30 minutes, rinsed 
with TBS, treated with 0.6% H2O2 in methanol, and rinsed again with TBS. Samples 
were then treated with either mouse anti-collagen type II IgG (Clone CII C1, DSHB, 
1:1000 in TBS) or mouse anti-collagen type I IgG (Sigma, diluted 1:1000 in TBS) for 1 
hour54. After incubation with rabbit anti-mouse IgG (horseradish peroxidase [HRP] 
conjugated, diluted 1:200 in TBS containing 1% bovine serum; Dako-P0260) for 30 min, 
the sections were rinsed and incubated for 30 min with goat anti-rabbit IgG (HRP 
conjugated, diluted 1:100 in TBS containing 1% bovine serum; Dako-P0448). Samples 
were stained with diaminobenzidine (DAB kit; Vector Laboratories, Burlingame, CA), 
and cell nuclei were counterstained with Mayer’s hemalum. Finally, stained samples 
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were embedded on microscope slides, using Aquatex (Merck KGaA, Darmstadt, 
Germany). Additional sections were stained for proteoglycans using toluidine-blue dye 
solution (0.0714% toluidine blue, Merck; 0.0714% pyronin Y, Fluka; and borax [0.143% 
di-sodium-tetra-borate], Merck) for 6 minutes as previously described26. For cell 
adhesion and spread area analyses, soluble KLD12 or RAD16-I (500 µg/mL in tissue 
culture water) were incubated overnight at 37°C in non-treated polystyrene culture plates. 
Plates were washed thoroughly with water and then incubated for at least 1 hour with the 
ITS+ media described above. BMSCs at 1.2x104 cells/cm2 were cultured for 2 hours in 
TGF-β1-containing medium before being fixed and processed for cytoskeletal imaging as 
described above. Five random fields were imaged using a Nikon Eclipse fluorescent 
microscope, and the cell area and number of cells per field were measured with the 
Matlab Image Processing Toolbox (The MathWorks, Natick, MA). 
 
Real-time Reverse-transcription Polymerase Chain Reaction 
RNA was extracted as described previously55. BMSC-seeded hydrogel disks were 
flash frozen in liquid nitrogen, pulverized, and homogenized in TRIzol reagent 
(Invitrogen).  RNA was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA) and 
quantified using a Nanodrop 1000 Spectrophotometer (Agilent Technologies, Santa Clara, 
CA). Absorbance measurements at 260 nm were used to determine the RNA 
concentration, and 1 µg of each sample was reverse transcribed using the AmpliTaq-Gold 
Reverse Transcription Kit (Applied Biosystems, Foster City CA).  Real-time RT-PCR 
was performed using the Applied Biosystems 7900HT and SYBR Green Master Mix 
(Applied Biosystems).  Expression of type I collagen, type II collagen, aggrecan, SOX9, 
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osteocalcin, PPAR-γ, and 18S were quantified using previously published primer 
sequences32,55,56.  For each timepoint and hydrogel sample, gene expression levels were 
first normalized by the corresponding 18S level for that sample, and then normalized by 
levels expressed by BMSC samples taken immediately prior to hydrogel encapsulation 
(Day 0)57. 
 
Biochemistry 
During the final 24 hours of culture at each timepoint, medium was additionally 
supplemented with 5 µCi/mL of 35S-sulfate and 10 µCi/mL of 3H-proline to measure 
cellular biosynthesis of proteoglycans and proteins, respectively. Upon completion of 
culture, four 30-minute rinses in excess non-labeled sulfate and proline were performed 
for all samples to wash out free radiolabel. Hydrogels were then weighed wet, lyophilized, 
and weighed dry. Samples were digested in 0.25 mg/mL proteinase-K (Roche Applied 
Science, Indianapolis, IN) overnight at 60°C.  Digested samples were assayed for total 
retained sulfated glycosaminoglycan (sGAG) content by DMMB dye binding assay58, 
DNA content by Hoechst dye binding59, and radiolabel incorporation with a liquid 
scintillation counter. Conditioned culture medium collected throughout the study was 
also analyzed for sGAG content by DMMB dye binding. 
 
Aggrecan Extraction and Western Analysis 
Aggrecan was extracted from hydrogel disks and analyzed as described 
previously60. Hydrogel disks were saturated with PBS and Complete Protease Inhibitors 
(Roche) and frozen at -20°C until extraction.  Gels were extracted for 48 hours in 4M 
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guanidinium hydrochloride, deglycosylated, and the resulting digest was lyophilized. 
Samples were reconstituted and 20 µg sGAG/lane was run on a 4-15% Tris-HCl gel at 
100V for 1 hour. Proteins were transferred to a nitrocellulose membrane and probed with 
affinity-purified antibodies for aggrecan G1 domain (JSCATEG)60. 
 
Statistical analysis 
DNA and sGAG content, and proteoglycan and protein biosynthesis, were 
reported as mean ± SEM with four samples from each of three animals (n=12).  RT-PCR 
results are reported as mean ± SEM using pooled samples from n=3 animals.  All data 
were log-transformed to ensure normality and analyzed by multi-factor ANOVA (with 
animal as a random factor) and post hoc Tukey tests with significance set at p<0.05. 
 
2.3 Results 
Cell and Actin Morphology 
Spherical, isolated, uniformly seeded cells were observed in all three scaffolds 
immediately after casting on day 0 (Fig. 2.2A) in both medium conditions (+TGF-β1 and 
Cntl). By day 4 in TGF-β1-supplemented medium, distinct morphologies were apparent 
in each of the hydrogels (Fig. 2.2B).  Cell-cell contact appeared to be a feature for both 
peptide hydrogels with a spread, networked morphology in RAD16-I peptide and a 
clustered morphology in KLD12 peptide. In control medium, cell spreading and apparent 
cell-cell contact were observed in both peptide hydrogels, similar to but less extensive 
than the respective +TGF-β1 conditions (not shown). At day 4, cells in agarose in both 
medium conditions maintained the same spherical, isolated morphology as at day 0, 
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suggesting that these cells did not reorganize their actin cytoskeleton (Fig. 2.2B). Despite 
these early differences, cells in all three hydrogels cultured with TGF-β1 had a more 
chondrocyte-like rounded morphology by day 21 (Fig. 2.2C),  showing that the apparent 
cell-cell contact seen at day 4 in peptide hydrogels was a temporary feature.  Using 
confocal microscopy, this predominantly-rounded cell morphology was confirmed for all 
three scaffolds at day 21 (Fig. 2.2D). To investigate the differences in BMSC 
morphology in RAD16-I and KLD12 hydrogel culture further, BMSCs were seeded on 
polystyrene surfaces with adsorbed RAD16-I or KLD12 peptide monomers.  After two 
hours, cells attached and spread to a significantly greater degree on RAD16-I surfaces 
than KLD12 (Fig. 2.3A).  Quantitative image analysis showed greater numbers of 
attaching cells per field, and more than double the area per cell, on RAD16-I peptide than 
on KLD12 surfaces (Fig. 2.3B). 
 
Chondrogenic, Osteogenic, and Adipogenic Gene Expression 
Evidence that chondrogenesis occurred in all three hydrogels was provided by the 
upregulation of three cartilage-associated genes, type II collagen, aggrecan, and SOX-9 
(Fig. 2.4B-D). As expected, TGF-β1-supplementation stimulated >100-fold upregulation 
of type II collagen and >1000-fold upregulation of aggrecan by day 4, with maximum 
upregulation at day 9 of >1000-fold and nearly 10,000-fold for type II collagen and 
aggrecan, respectively. In contrast, type I collagen, which is expressed by 
undifferentiated BMSCs and early in chondrogenesis45, was upregulated just 10-fold by 
day 4 with no further significant upregulation detected (Fig. 2.4A).  Upregulation of type 
II collagen and aggrecan also occurred in control medium, but the magnitude was 10 to 
 25
100-fold lower than with TGF-β1 (Figs. 2.4B & 2.4C).  No upregulation of type I 
collagen or SOX-9 was seen in control medium.  In all cases, these data showed no 
differences among the scaffolds, resulting in a similar overall gene expression pattern. 
Neither osteogenic nor adipogenic gene expression was observed in any of the 
scaffolds.  No significant differences were seen among scaffolds or medium conditions 
for osteocalcin, a marker for osteogenesis. At day 1, osteocalcin was downregulated by 
nearly 4-fold (Fig. 2.4E), but returned to baseline on days 4 through 9, and finally 
dropped again on day 14 to an average of 3-fold below day 0 levels. PPAR-γ expression, 
a marker for adipogenesis, was upregulated in control medium at days 4, 7, 9, and 14 by 
~5-fold in all three scaffolds (Fig. 2.4F); however, the addition of TGF-β1 reduced its 
expression to nearly baseline levels at all timepoints. 
 
Hydrogel DNA Content, sGAG Content, and ECM Biosynthesis 
Increases in DNA content were stimulated by TGF-β1-supplemented medium for 
both peptide hydrogels, but not in agarose, throughout the entire culture period (Fig. 2.5A, 
p<0.05).  This resulted in significantly higher DNA content for RAD16-I peptide than for 
agarose at all timepoints (p<0.001) and higher DNA content for KLD12 than for agarose 
cultures at days 14 and 21 (p<0.001). In addition, DNA content increased with time for 
both RAD16-I and KLD12 disks cultured in TGF-β1 supplemented medium resulting in 
significantly higher DNA content at day 21 vs. day 7 (p<0.001). 
TGF-β1 also stimulated a ~5-fold increase in sGAG content of all scaffolds at day 
7 (Fig. 2.5B, p<0.001) and a >10-fold increase at days 14 and 21 (p<0.001) relative to 
controls. sGAG content increased with time for all three hydrogels through day 14 
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(p<0.001). However, sGAG content only increased from day 14 to day 21 for the 
RAD16-I and KLD12 peptide hydrogels (p<0.001) resulting in nearly 2-fold higher 
sGAG content for both peptides compared to agarose (p<0.005). The percentage of 
sGAG retained in agarose hydrogels decreased with time in culture and was lower 
compared to RAD16-I or KLD12 peptides at day 21 (Table 1, p<0.001). In contrast, both 
RAD16-I and KLD12 peptides maintained constant sGAG retention throughout the 
culture period (Table 1) with modestly higher retention levels for RAD16-I peptide 
compared to KLD12 (p<0.05). 
Protein biosynthesis rates normalized to DNA content were 4-9 fold higher with 
TGF-β1 supplementation throughout the entire culture period (Fig. 2.5C, p<0.001), and 
decreased with time by a factor of 2-3 for day 21 vs. day 7 in all three hydrogels 
(p<0.005).  No differences in protein biosynthesis were seen among the three hydrogels. 
TGF-β1 stimulated 2-10 fold higher 35S-proteoglycan biosynthesis rates at all timepoints 
in all three hydrogels (Fig. 2.5D, p<0.01). Surprisingly (given the higher final sGAG 
content of the peptide hydrogels), 35S-proteoglycan biosynthesis, on a per-DNA basis, 
was 3-fold higher for agarose than for RAD16-I peptide (p<0.001).  However, 
proteoglycan biosynthesis increased in RAD16-I peptide by day 14 (p<0.05) (when 
proliferation had essentially stopped) and no significant differences were seen among the 
three hydrogels in TGF-β1-supplemented medium at days 14 or 21. 
 
Hydrogel Wet Weights and Contraction 
Both peptide hydrogels contracted 50%-60% within the first week of culture in 
the presence of TGF-β1 as assessed by changes in wet mass (Fig. 2.5E).  No further 
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contraction was observed after one week. In control medium, contraction of both peptide 
hydrogels was 30%-45% in the first week with no further contraction at later timepoints. 
No contraction was observed in agarose hydrogels in either medium condition. 
 
Hydrogel Histology - Accumulation of Proteoglycans and Collagen Types I and II 
Spatially uniform, metachromatic staining for the presence of sGAG was 
observed throughout both RAD16-I and KLD12 peptide hydrogels by day 21; in agarose, 
however, staining was largely confined to the immediate pericellular matrix (Fig. 2.6A). 
Positive type II collagen staining was also more intense and uniformly distributed 
throughout the RAD16-I and KLD12 peptide hydrogels than in the agarose, where again 
it was mainly in the pericellular matrix (Fig. 2.6B). Less intense non-uniform type I 
collagen staining was also visible in both peptide hydrogels, primarily in cell-associated 
regions whereas little or no staining was seen in agarose hydrogels (Fig. 2.6C). 
 
Aggrecan Western Blot 
GuHCl extracts from all three hydrogels revealed the presence of a large 
macromolecular species as detected by anti-G1 aggrecan Western blotting, running at the 
molecular weight of full length aggrecan (Fig. 2.7). In both RAD16-I and KLD12 
hydrogels, this full length aggrecan was the predominant species detected, while in 
agarose hydrogels a doublet-band near 65 kDa was the major immunoreactive product 
detected. This is consistent with the virtual absence of aggrecanase activity in the peptide 
gels in contrast to a high level in the agarose.  Since the agarose nonetheless accumulated 
quite high levels of GAG, it appears that it accumulates the CS-rich catabolic product of 
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aggrecanase activity cleaving the interglobular domain and resulting in the formation of 
abundant G1-NITEGE. This product is normally lost from cartilage explants61. 
 
2.4 Discussion 
The capacity for self-assembling peptide hydrogels to support and enhance 
chondrogenesis of 3D-encapsulated BMSCs was compared to that in agarose hydrogel 
culture. Both the DNA content and the accumulation of a cartilage-like ECM were higher 
for TGF-β1-stimulated BMSCs in RAD16-I and KLD12 hydrogels than in agarose. Due 
to contraction of both peptide hydrogels, but not agarose, normalization of data to wet 
mass (Fig. 2.5) would exaggerate the higher DNA content and ECM accumulation for 
peptide hydrogels.  Thus, the motivation for presenting the data on a per-hydrogel sample 
basis was to allow for a direct comparison of the neo-tissue construct in each hydrogel 
given an equal initial cell content and hydrogel size. The results are consequently 
consistent with a recent report where wet mass-normalized KLD12 peptide hydrogels had 
higher sGAG content than agarose hydrogels28, but are in contrast with the findings of 
Erickson41 which report higher sGAG content in agarose than in RAD16-I hydrogels.  
No significant differences in DNA-normalized protein and proteoglycan 
biosynthesis rates were observed for any of the three hydrogels in the presence of TGF-
β1 (with the exception of 35S-sulfate incorporation at day 7), however both DNA and 
sGAG content were higher for RAD16-I and KLD12 than for agarose. Thus, by 
presenting proteoglycan synthesis rates on a per-DNA basis, we have shown similar 
biosynthesis rates in both peptides and agarose. The finding that the biosynthetic rates 
were similar but the sGAG content was lower in agarose can probably be explained by 
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the lower cell content in agarose, the lower sGAG retention in agarose, or the presence of 
an intrinsic endocytotic removal mechanism for aggrecan sGAG in the agarose system 
especially. 
The three distinct cytoskeletal morphologies observed during the first week of 
culture suggest that unique biophysical signals are generated in each hydrogel. The 
mechanisms responsible for these differing cell morphologies are not known but may 
include the state of differentiation of the cells, the scaffold mechanical stiffness and cell-
scaffold adhesion44. For example, the equilibrium modulus of 2% agarose is ~10 kPa50,51 
which is approximately 10-fold higher than RAD16-I (~1 kPa storage modulus)53, while 
RAD16-I and KLD12 have stiffness values within 25% of each other52. The stiffer 
agarose thus likely confines cells to a spherical morphology and prevents cell mediated 
hydrogel contraction, consistent with recent reports where BMSC-seeded agarose 
maintained nearly constant volume and did not contract during long term culture30,41. 
Since the stiffness of RAD16-I and KLD12 are similar, differences in cell-scaffold 
adhesion/cell differentiation are likely more important for explaining the differences 
between the network of cell-cell contacts observed in RAD16-I and the multi-cell clusters 
in KLD12. To investigate this possibility, BMSCs were seeded onto 2D peptide-coated 
surfaces. More cells-per-field and greater spread-area per cell were observed for BMSCs 
on RAD16-I than on KLD12 during 2-hour adhesion experiments (Fig. 2.3). A recent 
report on HUVEC adhesion and spreading on RAD16-I and KLD12 hydrogels53 also 
showed more cells attaching and greater spreading per cell when seeded on RAD16-I 
compared to KLD12 hydrogels. These differences in adhesion are consistent with the 3D 
scaffold effects observed here, where more intimate cell-scaffold contact created by the 
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network morphology in RAD16-I may be due to greater cell-scaffold adhesion, while cell 
clusters in KLD12 may result from weaker cell-scaffold interactions. 
Two features seen in common to both peptides, but not agarose, were hydrogel 
contraction and extensive cell-cell contact.  In a recent review of biophysical signals in 
pre-natal chondrogenic condensations, Knothe Tate et al.44 reported that increasing cell 
density and cell-cell contact stimulates mitotic activity. Furthermore, the formation of 
cell condensations amplifies the number of cells which subsequently undergo overt 
chondrogenesis62,63. Thus, greater cell proliferation in both RAD16-I and KLD12 peptide 
hydrogels compared to agarose, as evidenced by higher DNA content, may be stimulated 
by cell-cell contact and the increased cell density generated by contraction of the peptide 
scaffolds.  Interestingly, a similar effect of contraction-stimulated mitotic activity was 
observed for chondrocytes seeded in a collagen-GAG scaffold64, although in this system, 
blocking contraction resulted in higher proteoglycan biosynthesis64,65. This contrasts with 
our current study, and may be a result of lower chondrogenic capacity of monolayer-
expanded chondrocytes compared to BMSCs. Given the importance of biophysical 
signals in chondrogenesis44, differences between the spread-network (RAD16-I) and 
clustered (KLD12) morphologies observed here (Fig. 2.2) may have important 
consequences for the final cell phenotype and neo-tissue composition produced in each 
peptide hydrogel, motivating more detailed studies of these differences. 
Two major chondrogenic ECM genes, type II collagen and aggrecan, were 
upregulated by over three orders of magnitude in all three hydrogels in the presence of 
TGF-β1 (Fig. 2.4). Consistent with recent reports on chondrogenesis of BMSCs in 
pellet66,67, agarose31,68, PEG46, and alginate18,32 culture, the sharpest increases in mRNA 
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transcript levels for type II collagen and aggrecan occurred during the first 3-7 days in 
culture, and transcript levels were nearly flat during the second week of culture (Fig. 2.4).  
Type I collagen, an important ECM molecule during early chondrogenesis in the 
developing limb bud44,45, was upregulated at day 4 with TGF-β1, but by substantially less 
than either type II collagen or aggrecan. SOX9 transcript levels were an order of 
magnitude higher with TGF-β1 by day 7, also consistent with recent reports in 
alginate32,46. Markers for osteogenesis (osteocalcin) and adipogenesis (PPAR-γ) were 
unchanged from their day 0 undifferentiated values in the presence of TGF-β1, 
demonstrating specific chondrogenic differentiation. Given that changes in cell 
morphology, hydrogel contraction, and the resulting cell-cell contacts occurred in peptide 
hydrogels during the first week of culture, and that concomitant upregulation of 
chondrogenic genes occurred in both agarose and peptide hydrogels during the first week, 
it is likely that critical cell differentiation decisions occur within the first few days after 
BMSC encapsulation in 3-D culture and exposure to TGF-β1. While no gene expression 
differences were measured between peptide and agarose hydrogels during this time, it is 
possible that the chondrogenic program can be easily modulated early in culture, 
suggesting further, detailed study of this phase of chondrogenesis. 
sGAG retention in agarose hydrogels dropped dramatically in the final week of 
culture but was maintained in both peptides.  This is in contrast to sGAG release from 
chondrocyte-seeded agarose cultures, which is constant over time50, but consistent with 
our results showing no additional accumulation of sGAG in agarose in the final week. 
sGAG accumulation in both peptide hydrogels, however, significantly increased during 
this time. Thus, while BMSCs in agarose and peptide hydrogels had similar DNA-
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normalized proteoglycan synthesis rates, the sGAG produced in agarose cultures was 
preferentially lost to the medium while that in peptide cultures was retained. This was 
confirmed by toluidine blue staining which indicated much higher negative charge 
content in the peptide gels compared to agarose cultures. The potential mechanisms for 
these differences in sGAG retention may be catabolic (i.e., the action of proteases 
cleaving aggrecan and thereby increasing release of sGAG) or anti-anabolic (i.e., the 
relative lack of production of ECM components necessary for aggrecan-sGAG retention 
such as link protein and/or hyaluronan, or the lower ECM density in agarose due to 
contraction differences).  To further understand the relative importance of these 
contrasting mechanisms, Western analysis with anti-G1 aggrecan antiserum was 
performed on hydrogel protein extracts (Fig. 2.6). Results showed a doublet at ~65 kDa 
in the agarose hydrogels samples only, consistent with aggrecanase-generated NITEGE-
neoepitope containing fragments61. Thus, an apparent high level of catabolic enzyme 
activity may have led to decreased sGAG retention in agarose, suggesting an important 
difference between the chondrogenic programs executed in agarose and peptide 
hydrogels. 
 
2.5 Summary 
The importance of scaffold design in promoting chondrogenesis of BMSCs for 
cartilage tissue engineering has been demonstrated through differences in ECM protein 
production, retention, and cell morphology.  Peptide hydrogels enhanced early 
chondrogenesis compared to agarose, and unique signals generated by each peptide 
sequence subtly altered the chondrogenic differentiation program. In addition to the 
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importance of scaffold-generated, biophysical signals, TGF-β1 was a critical biochemical 
signal necessary to promote chondrogenesis.  By further optimizing self-assembling 
peptide hydrogels, it may be possible to incorporate biochemical signals into the 
scaffold20. Self-assembling peptide hydrogels thus have the potential to incorporate both 
the appropriate biophysical and biochemical chondrogenic stimuli, making them a 
promising candidate for use in a clinically-feasible, cartilage repair therapy. 
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2.7 Tables 
Table 2.1 Percent sGAG Retained in Hydrogels Cultured with TGF-β1 
 (mean±sem; D7, D14, A, R, vs. Day 7, Day 14, Agarose, and RAD, respectively, p<0.05) 
 Day 7 Day 14 Day 21 
Agarose 62±3 59±2 44±3D7,D14
RAD16-I 80±4A 74±1A 73±1A
KLD12 57±4R 60±4R 59±5A,R
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2.8 Figures 
Cell-seeded
Hydrogel (50µL)
Acellular
Agarose Mold
12mm
1.6mm
6.35mm
 
Figure 2.1 Cell-encapsulation and self-assembly mold. 
The acelluar-agarose annulus mold is made by injecting 2% agarose into a custom, autoclavable 
frame. 50µL of cell-hydrogel suspension (BMSCs in RAD16-I, KLD12, or agarose) is then 
injected into the center to initiate self assembly. 
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A. Day 0 
   
B. Day 4 
   
C. Day 21 
   
D. Day 21 Confocal 
   
 Agarose RAD16-I KLD12 
 
Figure 2.2 BMSC F-actin Morphology in 3D Agarose, RAD16-I, and KLD12 
Representative 3D F-actin morphology images for BMSCs cultured with TGF-β1 
supplementation and encapsulated in agarose (left column), RAD16-I (center column) and 
KLD12 (right column). Culture duration was (A) 0 days, (B) 4 days, or (C) 21 days. (D) High 
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magnification, confocal images at day 21. Red indicates F-actin, blue indicates cell nuclei. Scale 
bar in (A) is applicable to (B) & (C), in all cases scale bar=50µm. 
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B. Quantitative Image Analysis 
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Figure 2.3 BMSC F-actin morphology on 2D RAD16-I & KLD12 Surfaces 
(A) Representative 2D F-actin morphology for BMSCs seeded onto RAD16-I (left) and KLD12 
(right) surfaces for 2 hours. Red indicates F-actin, blue indicates cell nuclei. (B) Quantification 
of 2D images, n=5 fields, field area = 5.61 x 10-3 cm2,  vs. RAD16-I, p<0.01. 
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Figure 2.4 Gene expression of 3D-encapsulated relative to monolayer BMSCs 
Cultured in control (Cntl) or TGF-β1 supplemented (+TGF) medium and encapsulated in 
agarose (Ag), RAD16-I (RAD), or KLD12 (KLD). All scaffolds measured at the same 
timepoints, but offset for readability. Stats: mean±sem; n=3 animals;  vs. Cntl medium; 1 or 
4 vs. day 1 or day 4, respectively; p<0.05. 
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C. Protein Biosynthesis
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E. Hydrogel Contraction
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Figure 2.5 Hydrogel Biochemistry and ECM Biosynthesis Rates 
Cultured in control (Cntl) or TGF-β1 supplemented (+TGF) medium and encapsulated in 
agarose (Ag), RAD16-I (RAD), or KLD12 (KLD). (A) DNA Content, (B) sGAG Content, (C) 
Protein Biosythesis, (D) Proteoglycan Synthesis. Stats: mean±sem; n=12 (4 gels x 3 animals); 
 vs. Cntl medium; 7 or 14 vs. day 7 or day 14, respectively; A or R vs. Agarose or RAD16-I, 
respectively; p<0.05. 
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A. Proteoglycan (Toluidine Blue) 
 
B. Collagen Type II 
 
C. Collagen Type I 
 
 Agarose RAD16-I KLD12 
D. IHC Controls: Bovine Cartilage-Bone Interface 
Cartilage
Bone
Cartilage
Bone
 
 Collagen Type I Collagen Type II 
Figure 2.6 Proteoglycan Histology and Collagen Immunohistochemistry 
(A) Representative toluidine blue staining for sGAG, and (B) collagen type II and (C) Type I 
immunohistochemistry images for BMSCs cultured with TGF-β1 supplementation in agarose 
(left column), RAD16-I (center column) and KLD12 (right column). (See Methods for details.) 
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Culture duration was 21 days. (D) Collagen I & II immunohistochemistry in bovine cartilage-
bone plugs as controls. Scale bar in (A) is applicable to (B), (C), & (D), in all cases scale 
bar=50µm. 
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Figure 2.7 Aggrecan Western Analysis 
Aggrecan extracted from BMSC-seeded agarose (Ag), RAD16-I (RAD), or KLD12 (KLD) 
hydrogels after 21 days in culture with TGF-β1 supplementation. Lanes 1-3 extracted from 
animal #1; lanes 4-5 extracted from animal #2. 
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The capacity for bone-marrow-stromal cells (BMSCs) and chondrocytes from 
young and adult equine donors to produce a cartilage-like ECM was investigated. Cells 
were isolated from animal-matched bone marrow and cartilage tissue, encapsulated in a 
self-assembling-peptide hydrogel, and cultured in a chemically-defined medium with and 
without TGF-β1 supplementation. BMSCs and chondrocytes from both donor ages were 
encapsulated with high viability. Young, but not adult chondrocytes proliferated in 
response to TGF-β1 while BMSCs from both ages proliferated with TGF-β1. Young 
chondrocytes stimulated by TGF-β1 accumulated ECM with 10-fold higher sulfated-
glycosaminoglycan content than adult chondrocytes and 2-3-fold higher than BMSCs of 
either age. The opposite trend was observed for hydroxyproline content, with BMSCs 
accumulating 2-3-fold more than chondrocytes, independent of age. BMSCs of either age 
produced neotissue with higher dynamic stiffness than young chondrocytes. Size-
exclusion chromatography of extracted proteoglycans showed that an aggrecan-like peak 
was the predominant sulfated proteoglycan for all cell types. Measurement of aggrecan 
core-protein length and chondroitin-sulfate-chain length by atomic-force microscopy 
revealed that independent of age, BMSCs produce longer core protein and chondroitin-
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sulfate chains, and fewer catabolic-cleavage products than chondrocytes, indicating that 
the BMSC-produced aggrecan has a younger phenotype than chondrocyte-produced 
aggrecan. Taken together these data suggest advantages for BMSCs over chondrocytes as 
a source for cell-based cartilage repair, especially for autologous applications with adult 
patients. 
 
3.1 Introduction 
Because of their capacity to undergo chondrogenesis14,16,66, bone-marrow derived 
stromal cells (BMSCs) have been the focus of numerous studies with the ultimate goal of 
repairing cartilage tissue damaged through disease or injury28,30,48. Recent reports have 
suggested a robust chondrogenic and tissue forming capacity for BMSCs that is sustained 
with aging19,69,70, in contrast with primary chondrocytes which have decreased matrix 
synthesis and tissue repair potential with age71-74. Decreased matrix production with age 
for primary chondrocytes may be due in part to their reduced sensitivity to pro-anabolic 
growth factors such as insulin-like growth factor-I or transforming growth factor-β1 
(TGF-β1)75-77. 
Several recent studies have encapsulated BMSCs in 3D hydrogel culture with 
TGF-β1/3 stimulation to induce chondrogenesis and compared the differentiated cell 
phenotype with that of primary chondrocytes30,41,48. While these studies have shown that 
chondrocytes produce a more cartilage-like and mechanically-functional ECM than 
BMSCs, these studies have all used a young bovine tissue source. Given the known 
phenotypic changes that occur with age for both chondrocytes and BMSCs, evaluation of 
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these cell types at multiple times during development and aging is important, especially 
in light of the potential advantages of using autologous tissue for cartilage repair29,78. 
To achieve cartilage repair, a successful cell-based strategy will be required to 
recapitulate the fine structure of the native cartilage ECM in order to produce a 
mechanically functional tissue. Aggrecan, a large aggregating proteoglycan, is the 
primary cartilage ECM molecule that provides the compressive stiffness and load 
distribution functions of the tissue79. Given the extensive changes in aggrecan 
biosynthesis80,81, processing82,83, aggregation72 and degradation79 with age, it will likely 
be important to evaluate the quality of aggrecan produced by any cell type used in a 
cartilage repair therapy. An intensively studied molecule, numerous techniques exist for 
the study of aggrecan including chromatography84 and Western analysis61, which assess 
size distribution and cleavage products in an entire population of  molecules, and imaging 
techniques such as electron microscopy85 and atomic force microscopy (AFM)60, which 
allow for detailed measurements of individual molecules. 
For this study, animal-matched equine bone marrow and cartilage tissue was 
harvested from both immature foal and skeletally-mature adult horses. BMSCs and 
chondrocytes were isolated and encapsulated in a self-assembling peptide hydrogel that 
has been shown to enhance chondrogenesis of BMSCs28 (Chapter 2). These peptides are 
being developed for use in cardiovascular20,86, liver42, and cartilage26, and have been 
successfully used in animal studies without inducing inflammation or immune 
response20,86, making them a candidate in vivo tissue engineering scaffold. Using TGF-β1 
to stimulate chondrogenesis and matrix production, we characterized the tissue forming 
capacity of BMSCs and chondrocytes from both young and adult animal sources over the 
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initial 21 days of tissue growth and quantitatively measured ECM synthesis and 
accumulation. The mechanical function of the developing ECM was assessed by dynamic 
compression testing. To further characterize the quality of the ECM, proteoglycans were 
extracted and characterized by size exclusion chromatography to examine the distribution 
of proteoglycan monomers. Proteoglycan extracts were also purified and imaged by 
atomic force microscopy to enable detailed morphological measurements of individual 
aggrecan molecules. 
 
3.2 Materials and Methods 
Materials 
KLD12 peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the 
MIT Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide 
synthesizer with FMOC protection. All other materials were purchased from the suppliers 
noted below. 
 
Tissue Harvest 
Cartilage tissue was harvested aseptically from the femoropatellar groove and 
bone marrow was harvested from the sternum and iliac crest of two immature (2-4-
month-old foals) and three skeletally-mature (2-5-year-old adults) mixed-breed horses as 
described previously.28  Horses were euthanized at Colorado State University for reasons 
unrelated to conditions that would affect either tissue. Bone marrow and cartilage tissue 
samples were animal-matched, as they were always harvested from the each animal. 
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Cell Isolation 
Chondrocytes were isolated by sequential pronase (Sigma-Aldrich, St. Louis, 
MO), collagenase (Roche Applied Science, Indianapolis, IN) digestion as described 
previously.87 Marrow samples were washed in PBS and fractionated by centrifugation to 
remove red blood cells.  BMSCs were isolated from the remaining nucleated cell pellet 
by differential adhesion as described previously.28 After BMSC colonies reached local 
confluence, cells were cryopreserved and stored in liquid nitrogen. Prior to peptide 
hydrogel encapsulation, BMSCs were thawed and plated at 6x103 cells/cm2 in low 
glucose DMEM plus 10% ES-FBS (Invitrogen Carlsbad, CA), HEPES, and PSA (100 
U/mL penicillin, 100 µg/mL streptomycin, and 250 ng/mL amphotericin) plus 5 ng/mL 
bFGF (R&D Systems, Minneapolis, MN). After 3 days, cells were detached with 0.05% 
trypsin/1mM EDTA (Invitrogen) at ~3x104 cells/cm2 (passage 1) and reseeded at 6x103 
cells/cm2. Over the subsequent 3 days, this expansion was repeated for passage 2 after 
which cells were detached for encapsulation in peptide hydrogels. 
 
Hydrogel Encapsulation and Culture 
BMSCs and chondrocytes were encapsulated in 0.35% (w/v) KLD12 peptide at a 
concentration of 10x106 cells/mL using acellular agarose casting molds to initiate peptide 
assembly as described previously (Chapter 2). Hydrogel disks with 50 µL initial volume 
and 6.35 mm diameter were cultured in high glucose DMEM (Invitrogen) supplemented 
with 1% ITS+1 (Sigma-Aldrich, St. Louis, MO), 0.1 µM dexamethasone (Sigma-Aldrich), 
37.5 µg/mL ascorbate-2-phosphate (Wako Chemicals, Richmond, VA), PSA, HEPES, 
Proline, sodium pyruvate, and NEAA, with (+TGF) or without (Cntl) 10 ng/mL 
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recombinant human TGF-β1 (R&D Systems) with medium changes every 2-3 days. For 
all assays except cell viability, hydrogels were cultured for 21 days. 
 
Cell Viability 
One day after encapsulation, cell-seeded-peptide hydrogels were stained with 350 
ng/mL ethidium bromide (dead) and 12.5 µg/mL fluorescein diacetate (live) in PBS and 
imaged with a Nikon Eclipse fluorescent microscope. 
 
DNA and ECM Biochemistry 
On day 20 of culture, medium was additionally supplemented with 5 µCi/mL of 
35S-sulfate and 10 µCi/mL of 3H-proline to measure cellular biosynthesis of 
proteoglycans and proteins, respectively. At day 21, hydrogels were rinsed 4x30-minutes 
in PBS with excess unlabeled sulfate and proline to remove excess free label. Hydrogels 
were weighed wet, lyophilized, weighed dry, and digested in 250 µg/mL proteinase-K 
(Roche) overnight at 60ºC. Digested samples were assayed for total DNA content by 
Hoechst dye binding59, retained sulfated glycosaminoglycan (sGAG) content by DMMB 
dye binding assay58, hydroxyproline (OH-Proline) content by chloramine T and p-
dimethylaminobenzaldehyde reaction58,88, and radiolabel incorporation with a liquid 
scintillation counter. Conditioned culture medium collected throughout the study was 
also analyzed for sGAG content by DMMB dye binding. 
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Mechanical Testing 
After 21 days of culture, hydrogels were placed in PBS with protease inhibitors 
(Protease Complete, Roche) and a digital image was captured from which plug cross-
sectional area was measured with the Matlab Image Processing Toolbox (The 
MathWorks, Natick, MA). For each cell type and medium condition, 6-9 hydrogel disks 
were tested (3 gels/animal x 2-3 animals). The dynamic stiffness of each plug was 
measured in unconfined uniaxial compression using a Dynastat mechanical spectrometer 
(IMASS, Hingham, MA) as described.89 A 15% offset strain was applied via 3x5% ramp-
and-hold steps (5% strain applied over 60 seconds, followed by 4-minute hold), followed 
by a frequency sweep of 0.5% amplitude sinusoidal strains at 0.05, 0.1, 0.3, 0.5, 1.0, and 
5.0 Hz. The dynamic compressive stiffness was calculated as the ratio of the fundamental 
amplitudes of stress to strain.89 
 
Proteoglycan Size-Exclusion Chromatography 
For the final 24 hours, hydrogels were cultured in medium supplemented with 50 
µCi/mL of 35S-sulfate. Proteins were extracted from the minced sample with 4M 
guanidine HCl and 100mM sodium acetate with protease inhibitors (Protease Complete, 
Roche) for 48 hours at 4ºC with agitation.82 Extract was desalted with a G-50 column 
(GE Healthcare Bio-Sciences, Piscataway, NJ), lyophilized and resuspended in 500mM 
ammonium acetate for separation on a Superose 6 column (GE Healthcare Bio-Sciences). 
35S-sulfate labeled proteoglycans were detected via an inline liquid scintillation counter. 
For native cartilage tissue extracts, 0.5mL fractions were collected and unlabeled 
proteoglycans were detected via DMMB dye binding. 
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 Aggrecan Monomer Extraction and AFM Sample Preparation 
Proteins were extracted from unlabeled, day 21 hydrogels with 4M guanidine as 
above. Extracts were adjusted to a density of 1.58 g/mL by the addition of CsCl and 
subjected to density gradient centrifugation at 470 000 gav for 72 hours at 4ºC. The 
gradient was fractionated and fractions were assayed for density and sGAG content by 
DMMB dye binding. Fractions were combined according to density with fractions >1.54 
g/mL (labeled D1)82. The D1 fraction was then desalted via dialysis and sGAG content 
was quantified by DMMB dye binding.  
Aggrecan samples for AFM imaging were prepared as described previously60. 
Muscovite mica surfaces (SPI Supplies, West Chester, PA, #1804 V-5) were treated with 
0.01% 3-amino-propyltriethoxysilane (APTES; Sigma Aldrich, St. Louis, MO) v/v in 
MilliQ water (18 MΩ · cm resistivity, Purelab Plus UV/UF, US Filter, Lowell, MA). 
Sixty microliters of APTES solution was deposited onto freshly cleaved mica, incubated 
for 20–30 min at room temperature in a humidity controlled environment, rinsed gently 
with MilliQ water, and air dried. The APTES-modified mica substrate was then incubated 
with 50 µL aliquots of 250 µg/ml GAG incubated for 20-30 min, gently rinsed with 
MilliQ water and air dried. Electrostatic interaction between the APTES-mica and the 
aggrecan GAG chains enabled retention of a population of aggrecan despite rinsing. 
Samples were imaged within a day of preparation. 
 
 50
AFM imaging 
Imaging was performed as described previously60. The Nanoscope IIIa Multimode 
AFM (Digital Instruments (DI), Santa Barbara, CA) was used to image all samples via 
the EV or JV scanners. Tapping mode was employed in ambient temperature and 
humidity using Olympus AC240TS-2 rectangular Si cantilevers (k = 2 N/m). The 
cantilever was driven just below resonant frequency, ω0, and a slow scan rate of 0.5-1 Hz 
was used to minimize sample disturbances giving a scan rate that was much slower (<25 
000x) than the tap rate. The scans were tested for typical AFM imaging artifacts by 
varying scan direction, scan size, and rotating the sample.  
The AFM height images were digitized into pixels and the aggrecan structure 
features were traced automatically with a custom Matlab program or manually with 
SigmaScan Pro image analysis software (SPSS Science, Chicago, IL). The core protein 
length and chondroitin sulfate GAG (CS-GAG) chain length were calculated according to 
the spatial coordinates of the traces. 
 
Statistical Analysis 
All data are presented as mean ± sem. Data were analyzed by a mixed model of 
variance with animal as a random factor. Residual plots were constructed for dependent 
variable data to test for normality and data were transformed if necessary to satisfy this 
assumption. Post hoc Tukey tests for significance of pairwise comparisons were 
performed with a threshold for significance of p<0.05.  
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3.3 Results 
Cell Viability and DNA Content 
Both BMSCs and chondrocytes from foal and adult donors survived seeding in 
peptide hydrogels and were >70% viable one day post-encapsulation in the presence of 
TGF-β1 (Fig. 3.1A). Similar viability was observed at day one in TGF-β1-free controls, 
however by day 21 decreased cell viability was apparent for both cell types and both 
donor ages in TGF-β1-free culture (not shown). No significant differences in DNA 
content were seen between days 0 and 21 for the TGF-β1-free controls suggesting 
minimal proliferation in these gels (Fig. 3.1B, note day 0 DNA content not available for 
adult BMSCs). In contrast, in the presence of TGF-β1, BMSC-seeded hydrogels from 
both foal and adult donors had approximately 2.5-fold higher DNA content than TGF-β1-
free controls (p<0.001). In addition, chondrocytes from foal donors also proliferated in 
response to TGF-β1, but to a slightly lesser degree than BMSCs, with a 1.6-fold increase 
in DNA vs. TGF-β1-free controls (p<0.001). When chondrocytes were isolated from 
adult donors however, they no longer proliferated in response to TGF-β1, demonstrating 
a different phenotype than chondrocytes from young donors (Fig. 3.1B).  
 
ECM Content and Biosynthesis 
As expected, foal-chondrocyte-seeded peptide hydrogels accumulated 
significantly higher sGAG than adult chondrocytes both with and without TGF-β174. In 
the absence of TGF-β1, accumulated sGAG was 7-fold higher for foal than for adult 
chondrocytes (Fig. 3.2A, p<0.001), and with TGF-β1 supplementation sGAG was more 
than 10-fold higher for the foal chondrocyte cultures (p<0.001). Minimal sGAG was 
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produced by BMSCs without TGF-β1 stimulation. However with TGF-β1 
supplementation, foal and adult BMSCs accumulated 3-fold and 6-fold higher sGAG than 
adult chondrocytes, respectively (p<0.001). In addition, these day 21 sGAG contents for 
foal and adult BMSCs were a factor of 2-3 lower than foal chondrocyte sGAG 
accumulation. 
 Consistent with the sGAG content data, foal-chondrocyte-seeded peptide 
hydrogels had higher per cell proteoglycan biosynthesis rates (measured by 35S-sulfate 
incorporation) than adult-chondrocyte hydrogels during the final day of culture (Fig. 
3.2B), although there was only a 2-fold difference between foal and adult chondrocytes, 
both with and without TGF-β1 (p<0.01). Proteoglycan biosynthesis in BMSC-seeded 
peptide hydrogels was minimal without TGF-β1 stimulation, but was approaching the 
level of foal chondrocytes in the presence of TGF-β1 with foal BMSC cultures only a 
factor of 2 lower (p<0.001) and adult BMSC statistically equivalent to foal chondrocyte 
hydrogels. 
 The fraction of sGAG retained vs. the total amount produced (retained plus lost to 
the conditioned medium) was highest for foal chondrocytes at 76% (Fig. 3.2C), but both 
foal and adult BMSCs were only approximately 25% lower (56% and 66%, respectively, 
p<0.001). In contrast, adult chondrocytes retained only 20% of the sGAG produced in the 
presence of TGF-β1, nearly a factor of 4 less than the foal chondrocytes (p<0.001). 
 The hydroxyproline content of chondrocyte-seeded peptide hydrogels showed 
similar but less pronounced trends compared to sGAG content. Foal chondrocytes 
accumulated 10% and 50% higher hydroxyproline than adult chondrocytes, without and 
with TGF-β1, respectively (Fig. 3.2D, p<0.001). In contrast to sGAG, production of 
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hydroxyproline by adult chondrocytes did not increase with TGF-β1 stimulation. Also in 
contrast to sGAG, BMSC-seeded peptide hydrogels had higher hydroxyproline content 
than chondrocyte-seeded hydrogels. Without TGF-β1, both foal and adult BMSC cultures 
had 30-40% higher hydroxyproline content than either foal or adult chondrocytes 
(p<0.001). With TGF-β1 supplementation, hydroxyproline content of BMSC cultures 
was approximately a factor of 2 higher than foal and a factor of 3 higher than adult 
chondrocytes (p<0.001). 
 Protein synthesis rates during the final day of culture (measured by 3H-proline 
incorporation) were largely consistent with total hydroxyproline content (Fig. 3.2E). In 
TGF-β1-free cultures the only significant difference was a lower rate for adult BMSC 
hydrogels by a factor of ~4 vs. the other cell types (p<0.001). TGF-β1 stimulation 
produced statistically comparable protein synthesis for adult and foal chondrocyte 
cultures with a 2- and 3-fold increase for foal- and adult-BMSC-seeded over 
chondrocyte-seeded peptide hydrogels, respectively (p<0.01). 
 The ratio of dry weight to wet weight, or the percentage solid, was higher for 
BMSC- than for chondrocyte-seeded peptide hydrogels, demonstrating greater total 
matrix density (Fig. 3.2F). In TGF-β1-free cultures, there was no significant difference 
between foal and adult chondrocytes (at approximately 1% solid), while foal and adult 
BMSCs were 20% and 80% higher, respectively (1.2% and 1.8%, p<0.05). Foal 
chondrocytes produced hydrogels that were nearly 2% solid with TGF-β1 stimulation, 
nearly 2-fold higher than adult chondrocytes (p<0.001). BMSCs were 2-3 fold higher still 
(p<0.001), at 4% and 6% solid for foal and adult BMSCs, respectively. 
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Mechanical Properties 
Dynamic stiffness trended with both frequency and cell type (Fig. 3.3, p<0.001). 
Pairwise comparisons revealed four statistically significant groups. The group with the 
highest dynamic stiffness was group A, which contained TGF-β1-stimulated hydrogels 
seeded with BMSCs from both foal and adult donors. Group B contained foal 
chondrocytes cultured in TGF-β1 and was less stiff than group A (p<0.05). Foal BMSCs 
and chondrocytes cultured in TGF-β1-free control medium were in group C, which was 
lower than group B (p<0.001). Finally, group D had the lowest stiffness (p<0.001) and 
consisted of adult chondrocytes cultured either with or without TGF-β1, as well as cell-
free controls. 
 
Proteoglycan Size-Exclusion Superose 6 Chromatography 
The majority of proteoglycans synthesized in all samples eluted as an aggrecan-
like peak similar to proteoglycans extracted from young bovine cartilage tissue (Fig. 3.4). 
Both foal BMSCs and chondrocytes also produced a low, broad peak, to the right of the 
aggrecan peak, that returned to baseline levels by Kav=0.3, suggesting a population of 
smaller proteoglycans was present in these samples84. All proteoglycans produced by 
adult BMSCs and chondrocytes eluted with a Kav less than 0.2, showing that these 
samples contained fewer small proteoglycans than the foal cells and were more similar to 
the native cartilage tissue extract. 
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Aggrecan Monomer Morphology AFM Imaging 
Purified proteoglycan extracts from BMSCs and chondrocytes of both animal 
ages contained molecules with a central backbone and numerous side chains, consistent 
with the known sGAG-functionalized core-protein structure of aggrecan (Fig. 3.5).60 In 
all samples, full-length aggrecan was observed (for selected examples see green arrows in 
Figs. 3.5A, 3.5D, 3.5G, 3.5J) and in many cases globular domains were visible on both 
ends of the core protein, consistent with the presence of both G1- and G3-globular 
domains. Quantitative image analysis revealed that BMSCs from both foals and adults 
produced core protein with significantly longer average core-protein length than 
chondrocytes, 487-503 nm vs. 412-437 nm, respectively (Fig. 3.6A, p<0.05). Further 
analysis of the distribution of core-protein length for all cell types (Fig. 3.6B) reveals a 
main peak near 600 nm, likely representing full-length aggrecan, and a tail that extends 
below 200 nm, likely due to catabolic processing of the aggrecan core protein. Consistent 
with the trends in Fig. 3.6A, the full-length aggrecan peak in Fig. 3.6B is shifted larger 
for BMSC samples, where the peak is ≥600 nm, than for chondrocyte samples, where the 
peak is <600 nm. Furthermore, the frequency of aggrecan cleavage products <300 nm in 
length is higher for chondrocytes than for BMSCs of the corresponding age donors (i.e. 
foal chondrocytes produce more cleavage products than foal BMSCs and similarly for 
adult chondrocytes vs. BMSCs). 
High magnification images of single aggrecan monomers have sufficient 
resolution to clearly distinguish and measure individual CS-GAG chains (example CS-
GAGs highlighted in green on Figs 5C, 5F, 5I, and 5L). CS-GAG chains on BMSC 
produced aggrecan were longer than on chondrocyte produced aggrecan for both foal 
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cells (Figs. 3.5E-F vs. 3.5 B-C) and adult cells (Figs. 3.5K-L vs. 3.5H-I). Image 
quantification confirmed this trend with BMSCs from both foals and adults producing 63-
73 nm CS-GAG chains while chondrocytes produced CS-GAG chains between 40-46 nm 
(Fig. 3.6A, p<0.05). 
 
3.4 Discussion 
The relative matrix forming capacity of BMSCs compared to that of primary 
chondrocytes was found to depend on the age of the tissue donor from which the cells are 
derived. For a skeletally-mature adult tissue source, BMSCs produced more sGAG and 
collagen and assembled a mechanically functional ECM with higher dynamic stiffness 
than primary chondrocytes. In addition, adult BMSCs proliferated during 3D peptide 
hydrogel culture in response to TGF-β1 stimulation, while adult primary chondrocytes 
did not. In contrast, BMSCs and chondrocytes from young tissue were both capable of 
proliferating and producing a mechanically functional tissue in 3D peptide hydrogel 
culture in the presence of TGF-β1. In the absence of TGF-β1, young primary 
chondrocytes demonstrated sGAG accumulation and proteoglycan synthesis that was 
greater than any other cell type in this study, but still not high enough to generate a tissue 
with more than an incremental increase in mechanical properties over cell-free controls. 
The conclusion that young BMSCs produce a comparable cartilage-like ECM to 
young chondrocytes is in contrast to several recent reports, including studies by Mauck et 
al.30, Erickson et al.41, and Connelly et al.,48 which showed inferior tissue forming 
capacity for BMSCs. However, these conclusions were all based on long-term, TGF-β1-
stimulated culture in agarose hydrogels, whereas the present study focused on the initial 
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21 days of culture in a self-assembling peptide hydrogel, which is known to enhance 
chondrogenesis of BMSCs relative to agarose (Chapter 2). When peptide hydrogels were 
used by Erickson et al., close agreement with our results was observed early in culture for 
both neotissue ECM content and dynamic mechanical stiffness. 
Young equine chondrocytes proliferated in response to TGF-β1, where adult 
equine chondrocytes did not, and had higher sGAG accumulation and proteoglycan 
synthesis than adult chondrocytes both with and without TGF-β1 stimulation. This is 
consistent with a recent report of decreased cellular proliferation and sGAG accumulation 
by human chondrocytes with age in pellet culture with TGF-β1 stimulation71. In addition, 
when Tran-Khanh et al. encapsulated bovine chondrocytes from fetal, young, and aged 
donors in agarose, a decrease in cell proliferation and sGAG per cell was observed with 
age74. However, Tran-Khanh et al. also saw a significant decrease in hydroxyproline 
content and protein synthesis per cell with age, which was not observed in the present 
study. 
The dynamic stiffness of BMSC-seeded hydrogels from both young and adult 
sources was higher than for young chondrocytes, despite the higher sGAG content for 
young chondrocyte-seeded hydrogels, suggesting that a model where stiffness is linearly 
related to sGAG content is insufficient to describe these data. Given that dynamic 
stiffness was a function of frequency, a time-dependent model, such as poroelasticity, is 
required to describe the mechanical properties of the developing tissue constructs89. 
Poroelasticity predicts that mechanical properties will depend on both the equilibrium 
modulus and the hydraulic permeability of the solid matrix. While the equilibrium 
modulus and hydraulic permeability are both dependent on the sGAG content of the 
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neotissue, they also depend on the density of the solid matrix90. Since both young and 
adult BMSCs produced a denser solid matrix (with TGF-β1) than young chondrocytes, a 
lower hydraulic permeability may be expected than for BMSCs than for young 
chondrocytes. This higher solid matrix density and resulting lower hydraulic permeability 
for BMSC-seeded hydrogels corresponds to the higher dynamic stiffness measured for 
BMSC than for young chondrocyte samples, suggesting a poroelastic description for cell-
seeded peptide hydrogel mechanical properties. 
Size exclusion chromatography of the proteoglycans extracted from developing 
ECM of BMSC- and chondrocyte-seeded peptide hydrogels revealed that the 
predominant peak detected ran in the void volume of a Superose 6 column consistent 
with the size of aggrecan84. This aggrecan peak was observed from ECM extracts from 
both young and adult cells. However, for both young BMSCs and chondrocytes an 
additional minor population of proteoglycans was observed near Kav = 0.2 consistent with 
the size of decorin84, whereas adult BMSCs and chondrocyte samples did not appear to 
contain a population of small proteoglycans. Due to the resolution limitations of the 
Superose 6 column in separating the various cleavage products of aggrecan monomers, 
more detailed analyses were performed via AFM imaging.  In general, chromatography 
detected predominantly full-length aggrecan, which was generally consistent with the 
histograms of core-protein length observed by AFM imaging. 
When purified aggrecan was imaged by tapping-mode AFM, predominantly full-
length aggrecan monomers were observed for BMSCs and chondrocytes from both young 
and adult donors. This is in contrast to reports of significant variability in aggrecan size 
with age that were attributed to variation in core protein length82,83,85. These differences 
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are likely due to the use of primary tissue extracted aggrecan, which has a tissue half-life 
of 3.5 years79, as compared to the newly synthesized aggrecan in the current study. Due 
to this long residence time, tissue-extracted aggrecan is susceptible to sustained catabolic 
activity91 generating trends with age that were not seen in the present study. Nonetheless, 
aggrecan cleavage products were observed, although differences were mainly between 
chondrocytes and BMSCs and not related to age. One potential explanation for the 
difference in cleavage product formation is that TGF-β1 stimulation has been shown to 
increase catabolic processing of aggrecan in chondrocyte-seeded agarose92. In contrast, 
aggrecan catabolic activity by BMSCs in TGF-β1 stimulated peptide hydrogels is limited 
(Chapter 2). Thus, the observed catabolic processing of aggrecan may be a cell-type 
specific response to TGF-β1 stimulation. 
In addition to differences in aggrecan cleavage product production, longer core-
protein length for full-length aggrecan was observed for BMSCs than for chondrocytes. 
The trend for longer full-length aggrecan molecules produced in BMSC cultures may be 
related to the difference in CS-GAG chain length between the two cell types. BMSC 
samples had 40%-75% longer CS-GAG chains than chondrocyte samples. Given the high 
anionic charge density of these CS-GAGs and their close packing attachment on the core 
protein, an increase in their length would lead to a higher charge density and increased 
repulsive force, which would be expected to extend the core protein60.  
One potential mechanism by which longer CS-GAG chains may be synthesized is 
through altered core-protein post-translational processing kinetics80,81,93. These reports 
showed that slowing the rate of aggrecan core protein synthesis leads to a reduction in the 
rate of intracellular processing of core protein, which resulted in the synthesis of longer 
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CS-GAG chains. This effect was observed both for chemical inhibition of core protein 
synthesis by cycloheximide80,81 and for mechanical inhibition of core protein synthesis by 
static compression93. To investigate whether a lower core protein synthesis rate in BMSC 
than in chondrocyte cultures would explain the longer CS-GAG chains observed for 
BMSCs, the rate of core protein synthesis was estimated by dividing the 35S-sulfate 
incorporation rate (Fig. 3.2B) by the average CS-GAG chain length (Fig. 3.6A). The 
result is plotted in Fig. 3.7 along with rescaled CS-GAG data from Fig. 3.6A. Core 
protein synthesis for foal chondrocytes was 2-4-fold higher than for adult BMSCs, adult 
chondrocytes and foal BMSCs (p<0.001), while core protein synthesis rate differences 
between these three cell types were not significant (Fig. 3.7). These results showed an 
inverse relationship between core protein synthesis and CS-GAG chain length, with 
longer CS-GAG chains produced by BMSCs corresponding to lower core protein 
synthesis rates. Conversely, the higher core protein synthesis rate for foal chondrocytes 
corresponded with shorter CS-GAG chains. Adult chondrocytes were the exception to 
this trend, producing CS-GAG chains that were as short as foal chondrocytes, yet 
synthesizing core protein at a rate that was as low as BMSC samples. This suggests that a 
reduction in the post-translational processing capacity of adult chondrocytes compared to 
the other three cell types, and that this reduction is potentially responsible for the shorter 
CS-GAG chains produced. 
 
3.5 Summary 
BMSCs encapsulated in a self-assembling peptide hydrogel demonstrated robust 
cartilage ECM forming capacity that was sustained with aging, whereas similarly 
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cultured chondrocytes had reduced ECM forming capacity with age. The newly secreted 
ECM was mechanically functional and the matrix biochemical composition was 
consistent with a poroelastic model for the measured mechanical moduli. Detailed 
analysis of aggrecan monomers synthesized by BMSCs and chondrocytes, revealed 
longer core-protein length and CS-GAG chain length for BMSCs than for chondrocytes 
consistent with the synthesis of a younger tissue phenotype by BMSCs72,82,83. Taken 
together these differences suggest potential advantages for BMSCs over chondrocytes for 
use in cell-seeded cartilage repair strategies, especially when it is desirable to use 
autologous cells for treatment of adult patients. Future work on BMSC based therapies 
will need to develop techniques for maintaining the chondrogenic phenotype established 
during the early chondrogenesis described in this study, without inducing hypertrophy 
and terminal differentiation. These techniques could potentially involve modifying the 
cell-culture scaffold with bioactive motifs to control the BMSC differentiation state 
throughout the course of neotissue formation, integration with surrounding native tissue, 
and return to full mechanical and physiologic function. 
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3.7 Figures 
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Figure 3.1 Cell Viability and Hydrogel DNA Content 
(A) Live (green) and dead (red) staining of cell-seeded, self-assembling peptide hydrogels 
cultured with TGF-β1 at day 1. (B) DNA content for chondrocyte (Chd) and BMSC seeded 
hydrogels at day 0 (Day 0), or after 21 days of culture in control (Cntl D21) or TGF-β1 
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supplemented (TGF D21) medium. Stats: mean ± sem, n=8 (4 gels x 2 foals), n=12 (4 gels x 3 
adults); # vs. Day 0; * vs. Cntl D21; p<0.001. 
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Figure 3.2 Hydrogel ECM Biosythesis Rates and Content 
Chondrocyte (Chd) and BMSC seeded peptide hydrogels after 21 days of culture in control 
(Cntl D21) or TGF-β1 supplemented (TGF D21) medium. (A) sGAG content (B) Proteoglycan 
biosynthesis (C) Percent sGAG retention (hydrogel retained / total produced including lost to 
medium) (D) Hydroxyproline content (E) Protein biosynthesis (F) Percent solid matrix (dry 
weight / wet weight). Stats: mean ± sem, n=8 (4 gels x 2 foals) or n=12 (4 gels x 3 adults); * vs. 
Cntl D21; ‡ vs. foal chondrocyte; † vs. adult chondrocyte; p<0.05. 
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Figure 3.3 Hydrogel Dynamic Stiffness 
Chondrocyte (Chd) and BMSC seeded peptide hydrogels after 21 days of culture in control (Ctl) 
or TGF-β1 supplemented (TGF) medium. Stats: mean ± sem, n=6 (3 gels x 2 foals) or n=9 (3 
gels x 3 adults); a, b, c, d statistically unique groups; p<0.05. 
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Figure 3.4 Superose 6, Size-Exclusion, Proteoglycan Chromatography 
Proteoglycans extracted from either chondrocyte and BMSC seeded peptide hydrogels after 21 
days of culture with TGF-β1 or from native cartilage tissue harvested from newborn bovine 
calves. 
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Figure 3.5 Tapping-mode AFM Imaging of Aggrecan Monomer Morphology 
Proteoglycans extracted from cell-seeded peptide hydrogels after 21 days of culture with TGF-β1. 
(A-C) Foal chondrocytes, (D-F) Foal BMSCs, (G-I) Adult chondrocytes, (J-L) Adult BMSCs. 
Green arrows in A, D, G, and J denote ends of full-length aggrecan monomers. Example 
individual CS-GAG chains highlighted in green in C, F, I, and L.  
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Figure 3.6 Aggrecan AFM Image Quantification 
Aggrecan extracted from chondrocyte (Chd) and BMSC seeded peptide hydrogels after 21 days 
of culture with TGF-β1. (A) Core-protein length and CS-GAG chain length (B) Histogram of 
core-protein length. Stats: mean ± sem; core-protein length: a, b statistically unique groups, 
n=110-231; CS-GAG length: c, d statistically unique groups, n=28-35; p<0.05. 
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Figure 3.7 Core Protein Synthesis Rate and CS-GAG Chain Length 
Chondrocyte (Chd) and BMSC seeded peptide hydrogels after 21 days of culture with TGF-β1. 
Core protein synthesis rate calculated by normalizing the 35S-sulfate proteoglycan synthesis rate 
in Fig. 3.2B to the CS-GAG chain length in Fig. 3.6A (units=pmol/hr/µg DNA/nm). Stats: mean 
± sem; core protein synthesis: a, b statistically unique groups, n=8-12; CS-GAG length: c, d 
statistically unique groups, n=28-35; p<0.05. 
 
 70
Chapter 4. Controlled delivery of TGF-β1 from self-assembling 
peptide hydrogels induces chondrogenesis in bone marrow 
stromal cells via Smad 2/3 signaling 
4.1 Introduction................................................................................................................. 72 
4.2 Materials and Methods................................................................................................ 74 
4.3 Results......................................................................................................................... 79 
4.4 Discussion ................................................................................................................... 85 
4.5 Summary ..................................................................................................................... 89 
4.6 Acknowledgements..................................................................................................... 89 
4.7 Tables.......................................................................................................................... 91 
4.8 Figures......................................................................................................................... 91 
 
Self-assembling peptide hydrogels were modified to deliver TGF-β1 to encapsulated 
bone-marrow derived stromal cells (BMSCs) via biotin-streptavidin tethering and growth 
factor adsorption. BMSCs encapsulated in peptide hydrogels with both tethered and 
adsorbed TGF-β1 were cultured in TGF-β1-free medium, and chondrogenesis was 
compared to that for BMSCs encapsulated in unmodified peptide hydrogels, with and 
without medium-delivered TGF-β1. Adsorbed TGF-β1 peptide hydrogels stimulated 
chondrogenesis of BMSCs as demonstrated by cell proliferation and cartilage-like ECM 
accumulation, while tethered TGF-β1 was not different from TGF-β1-free controls. 
Adsorbed TGF-β1 in both acellular peptide and agarose hydrogels was retained for 21 
days with repeated bath changes, and peptide hydrogels retained 3-fold more TGF-β1 
than agarose. Full-length aggrecan was produced by BMSCs in response to adsorbed 
TGF-β1 in both peptide and agarose hydrogels, while medium-delivered TGF-β1 
stimulated elevated aggrecan cleavage product formation in agarose. Smad 2/3 was 
phosphorylated transiently in response to adsorbed TGF-β1, while medium-delivered 
TGF-β1 produced sustained signaling, suggesting dose and signal duration are potentially 
important for minimizing aggrecan cleavage product formation. TGF-β1 adsorbed to self-
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assembling peptide hydrogels can stimulate BMSC chondrogenesis and neotissue 
production for cartilage tissue engineering applications. 
 
4.1 Introduction 
Due to the poor regenerative capacity of cartilage after injury or disease, cell-
based, tissue-engineering strategies have been proposed to repair cartilage defects, 
resurface arthritic joints, and restore mechanical and physiologic tissue functions. To 
deliver a cell-based therapy, tissue engineering scaffolds seeded with bone-marrow-
derived stromal cells (BMSCs) have been extensively studied with the goal of delivering 
and retaining cells in irregular defects, providing an appropriate environment for cell 
attachment, migration, proliferation, and differentiation, and stimulating production of 
cartilage neotissue that integrates with the surrounding native tissue13,29,38. To achieve all 
of these goals, a feature likely to be of critical importance will be to incorporate into 
scaffold design bioactive motifs which induce chondrogenesis and promote cartilage 
ECM synthesis13. 
Transforming growth factor β1 (TGF-β1) has been widely used to promote 
chondrogenesis of BMSCs in a variety of culture systems by supplying it in the medium 
for the duration of culture16,31,32. Due to the short in vivo half-life of TGF-β isoforms and 
their potent action on other cell types, various technologies have been engineered with 
the goal of local delivery and controlled release of these growth factors in vivo94-99. Given 
the wide range of functions controlled by TGF-β1100-102, the goal of any such technology 
is to stimulate the appropriate intracellular signals to generate the desired effect on cell 
function. TGF-β1 signals through binding its type I and II receptor serine/threonine 
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kinases on the cell surface, forming an active complex that phosphorylates the Smad 
proteins, which in turn propagate the signal by ultimately translocating to the nucleus and 
promoting transcription101,102. The activated TGF-β1 receptor complex directly 
phosphorylates Smad2 and Smad3, two of the receptor-activated Smad proteins, to 
initiate this signal transduction pathway100. 
Self-assembling peptide hydrogels are a versatile new class of materials that have 
been developed for tissue engineering applications22,103-106. Benefits have been 
demonstrated for the use of these peptide hydrogels in cartilage26,28, liver42, and 
cardiovascular20,86 tissue, and they have been shown to provide a microenvironment 
which enhances the chondrogenesis of BMSCs28 (Chapter 2). These peptides can also 
control the delivery and release of functional proteins104, therapeutic macromolecules105, 
and bioactive motifs103. Taken together, these studies suggest the potential to 
simultaneously co-encapsulate growth factors and BMSCs in self-assembling peptide 
hydrogels and generate cartilage neotissue. 
The goal of this study was to deliver TGF-β1 within a self-assembling peptide 
hydrogel to induce chondrogenesis of encapsulated BMSCs and the subsequent 
accumulation of a cartilage-like ECM. Two strategies for coupling TGF-β1 to the peptide 
scaffold were tested.  The first employed biotin-conjugated TGF-β1 (bTGF-β1), biotin-
conjugated peptide monomers, and multivalent streptavidin, which tethered TGF-β1 to 
the scaffold through a high-affinity “biotin sandwich” bond20. The second was to 
nonspecifically adsorb TGF-β1 to the unassembled-peptide hydrogel prior to 
encapsulating BMSCs. Functional assays for chondrogenesis of encapsulated BMSCs 
included cell content and biosynthesis of cartilage ECM components in cultured 
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hydrogels. TGF-β1 binding and release was characterized by release of radiolabeled 
growth factor from acellular peptide and agarose hydrogels. Finally, bioactivity of the 
peptide-delivered TGF-β1 was confirmed by Western blot analysis of phosphorylated 
Smad 2/3. 
 
4.2 Materials and Methods 
Materials 
KLD peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the 
MIT Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide 
synthesizer with FMOC protection. All other materials were purchased from the suppliers 
noted below. 
 
Tissue Harvest 
Equine bone marrow was harvested from the sternum and iliac crest of immature 
(2-4-month-old foals) and skeletally-mature (2-5-year-old adults) mixed-breed horses as 
described previously.28 Horses were euthanized at Colorado State for reasons unrelated to 
conditions that would affect bone marrow. Bovine bone marrow was harvested from 
newborn bovine calves (Research 87, Marlborough, MA). 
 
Cell Isolation 
BMSCs were isolated from equine (Chapter 3) and bovine (Chapter 2) marrow as 
described previously. Differential adhesion was used to separate BMSCs from the total 
nucleated cell population.28 After reaching local confluence, BMSCs were cryopreserved 
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and stored for future use. Prior to peptide hydrogel encapsulation, BMSCs were expanded 
by plating at 6x103 cells/cm2 and culturing for three days in low glucose DMEM, 10% 
ES-FBS (Invitrogen, Carlsbad, CA), HEPES and PSA (100 U/mL penicillin, 100 µg/mL 
streptomycin, and 250 ng/mL amphotericin) plus 5 ng/mL bFGF (R&D Systems, 
Minneapolis, MN). After 3 days, cells were detached with 0.05% trypsin/1mM EDTA 
(Invitrogen) at ~3x104 cells/cm2 (passage 1) and replated at 6x103 cells/cm2. Passage 2 
cells were used for 3D peptide hydrogel culture. 
 
Hydrogel Encapsulation and Culture 
BMSCs were encapsulated in 0.35% (w/v) KLD or 2% low-melting-point 
Agarose (Invitrogen) using acellular agarose molds to initiate self-assembly (Chapter 2) 
and the resulting 50 µL initial volume, 6.35 mm diameter disks were cultured in high 
glucose DMEM (Invitrogen) supplemented with 1% ITS+1 (Sigma-Aldrich, St. Louis, 
MO), 0.1 µM dexamethasone (Sigma-Aldrich), 37.5 µg/mL ascorbate-2-phosphate 
(Wako Chemicals, Richmond, VA), PSA, HEPES, Proline, sodium pyruvate, and NEAA, 
with (TGF) or without (control) 10 ng/mL recombinant human TGF-β1 (R&D Systems). 
For TGF-β1 takeaway experiments, hydrogels were cultured in TGF-β1-supplemented 
medium for 4, 7, or 14 days followed by culture in control (TGF-β1-free) medium for the 
remainder of 21 days. BMSCs were alternatively encapsulated in either TGF-β1 tethered 
KLD (Teth-KLD): 0.35% KLD with 35 µg/mL biotin-KLD [biotin-(aminocaproic acid)3-
(KLDL)3], 2.1 µg/mL streptavidin (Pierce Biotechnology, Rockford, IL) and 100 ng/mL 
biotin-conjugated TGF-β1 (bTGF-β1, R&D Systems) or TGF-β1 adsorbed KLD (Ads-
KLD): 0.35% KLD with 100 ng/mL unlabeled TGF-β1 (R&D Systems). Both Teth-KLD 
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and Ads-KLD hydrogels were cultured in control (TGF-β1-free) medium. Hydrogels 
were cultured for up to 21 days. 
 
DNA and ECM Biochemistry 
During the last 24 hours of culture, medium was additionally supplemented with 5 
µCi/mL of 35S-sulfate and 10 µCi/mL of 3H-proline to measure cellular biosynthesis of 
proteoglycans and proteins, respectively. Upon termination of culture, hydrogels were 
rinsed 4x30 minutes in excess unlabeled sulfate and proline, weighed wet, lyophilized, 
weighed dry, and digested in 250 µg/mL proteinase-K (Roche Applied Science, 
Indianapolis, IN) overnight at 60ºC. Digested samples were assayed for total DNA 
content by Hoechst dye binding59, retained sulfated glycosaminoglycan (sGAG) content 
by DMMB dye binding assay58, and radiolabel incorporation with a liquid scintillation 
counter. Conditioned culture medium collected throughout the study was also analyzed 
for sGAG content by DMMB dye binding. 
 
TGF-β1 Controlled Delivery and Peptide Hydrogel Uptake 
Immediately before use, 125I-TGF-β1 (PerkinElmer, Waltham, MA) was purified 
by Sephadex G25 chromatography to remove small 125I species that may result from 
time-dependent degradation of the label or incomplete purification as received from the 
supplier107. Sephadex G25 chromatography was performed with a 0.7 × 50 cm gravity fed 
column equilibrated in 1 M acetic acid supplemented with 0.1% BSA and 0.1% Triton X-
100. Purified 125I-TGF-β1 was collected in the void volume. Acellular 0.35% (w/v) KLD 
or 2% agarose solutions with and without 125I-TGF-β1 (55pM, 1.4 ng/mL, 3500 
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Ci/mmol) or unlabeled TGF-β1 (10-100 ng/mL) were cast in acellular agarose molds as 
above. Hydrogels were incubated at 37ºC with agitation in a bath consisting of high 
glucose DMEM with 1% ITS+1 (Sigma-Aldrich), PSA, HEPES, Proline, sodium 
pyruvate, and NEAA. For TGF-β1 controlled delivery, the bath was changed every 2-3 
days and saved for the duration of the experiment. At day 21, hydrogels were rinsed 3x to 
remove surface-bound TGF-β1 and mechanically disrupted (KLD) or melted (agarose) to 
measure retained TGF-β1. For peptide hydrogel TGF-β1 uptake, 125I-TGF-β1 was added 
to the bath where indicated and the bath was not changed for 5 days. Bath and hydrogel 
samples were collected as before. The 125I-radioactivity of all bath and hydrogel samples 
were quantified individually using a gamma counter. To account for the presence of small 
labeled species accumulated during the timecourse of experimentation, Sephadex G25 
chromatography of the bath was performed weekly and at the end of all experiments and 
the fraction of free 125I was determined107. The uptake ratio of free 125I was also measured 
separately and included in the correction. 
 
Aggrecan Extraction and Western Analysis 
Aggrecan was extracted from hydrogel disks and analyzed as described 
previously60. Hydrogel disks were saturated with PBS and Complete Protease Inhibitors 
(Roche) and frozen at -20°C until extraction.  Gels were extracted for 48 hours in 4M 
guanidinium hydrochloride, deglycosylated, and the resulting digest was lyophilized. 
Samples were reconstituted and 20 µg sGAG/lane was run on a 4-15% Tris-HCl gel at 
100V for 1 hour. Proteins were transferred to a nitrocellulose membrane and probed with 
affinity-purified antibodies for aggrecan G1 domain (JSCATEG)60. 
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 Smad 2/3 and pSmad 2/3 Western Analysis 
Hydrogels were mechanically disrupted via pipetting with extraction buffer 
consisting of Tris, NaCl, Triton X-100, and NP-40 with protease and phosphatase 
inhibitors. Extracts were sonicated, frozen, and stored in liquid nitrogen. For Western 
analysis, samples were thawed, vortexed, and analyzed for DNA content by Hoechst dye 
binding. Proteins were separated by 10% SDS-PAGE loaded with 0.1 µg DNA per lane. 
Proteins were transferred to a PVDF membrane and probed with Smad 2/3 or pSmad2 
primary antibodies (Cell Signaling Technology, Danvers, MA) and HRP-conjugated, 
anti-rabbit secondary antibody.  Membranes were stripped and reprobed with β-actin 
primary antibody (Cell Signaling Technology). For semi-quantification, band 
densitometry was performed using AlphaEaseFC (Alpha Innotech, Inc., San Leandro, 
CA) and Smad2/3 and pSmad2 were normalized both to β-actin as a loading control and 
to the day 4, medium-delivered TGF-β1 sample on each membrane. 
 
Statistical analysis 
All data are presented as mean ± sem. Data were analyzed with a mixed model of 
variance with animal as a random factor. Residual plots for dependent variable data were 
constructed to test for normal distribution. If this assumption was not met, data were 
transformed to ensure normality. Pairwise comparisons were made by post hoc Tukey 
tests with significance threshold set at p<0.05. 
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4.3 Results 
bTGF-β1 Bioactivity and Peptide Hydrogel Tethering 
The bioactivity of bTGF-β1 was verified by culturing bovine-BMSC-seeded 
peptide hydrogels in medium supplemented with both bTGF-β1 and TGF-β1 for 14 days. 
Peptide hydrogels cultured in bTGF-β1 and TGF-β1 accumulated 38 µg and 64 µg of 
sGAG, respectively, and both were significantly greater than 5 µg sGAG accumulated in 
TGF-β1-free controls (p<0.001). In addition, proteoglycan biosynthesis for bTGF-β1, 
TGF-β1, and TGF-β1-free controls were 109, 151, and 17 pmol/hr/µg DNA, respectively, 
with bTGF-β1 and TGF-β1 both significantly greater than TGF-β1-free (p<0.001). Thus, 
by both sGAG accumulation and proteoglycan biosynthesis bTGF-β1 stimulated 
chondrogenic differentiation of bovine BMSCs. 
 When combined with a molar excess of multivalent streptavidin, bTGF-β1 can be 
tethered to the biotinylated-KLD hydrogel via a high-affinity noncovalent bond (Teth-
KLD). When bovine BMSCs were encapsulated in Teth-KLD and cultured for 14 days, 
no significant differences from TGF-β1-free controls were seen in either DNA or sGAG 
content (Fig. 4.1). However, with TGF-β1-supplemented medium non-tethered hydrogels 
had 4-fold higher DNA content than Teth-KLD by day 7 (Fig. 4.1A, p<0.001), which 
remained nearly 3-fold higher at day 14 (p<0.001). Similarly, sGAG content for 
untethered hydrogels with TGF-β1-supplemented medium was more than 6-fold higher 
than Teth-KLD at day 7 (Fig. 4.1B, p<0.001) and increased to nearly 18-fold higher by 
day 14 (p<0.001). 
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TGF-β1 Medium Takeaway 
To investigate the duration of TGF-β1 medium supplementation required to 
stimulate chondrogenesis, TGF-β1 was removed from the culture medium at several 
timepoints during a 21-day culture experiment (Fig. 4.2). With only 4 days of culture in 
TGF-β1-supplemented medium, followed by 17 days of culture in TGF-β1-free medium, 
the DNA content of adult equine BMSC-seeded hydrogels was statistically equivalent to 
culture with 21 days of TGF-β1 stimulation (Fig. 4.2A) and more than 2-fold higher than 
TGF-β1-free controls (p<0.001). sGAG accumulation was more than 20-fold higher with 
4 days of TGF-β1 stimulation than with TGF-β1-free culture (Fig. 4.2B, p<0.001).  
Furthermore sGAG accumulation with 4 days of TGF-β1 was only 30% lower than with 
21 days of TGF-β1 supplementation (p<0.01).  
 Protein biosynthesis during day 20-21 of culture for hydrogels that were 
stimulated with TGF-β1 for the initial 4 days was more than 3-fold higher than TGF-β1-
free controls (Fig. 4.2C, p<0.001) and was 10% of continuous TGF-β1 supplemented 
hydrogels (p<0.001). Proteoglycan biosynthesis for 4-day TGF-β1-stimulated hydrogels 
was nearly 5-fold higher than TGF-β1-free controls (Fig. 4.2D, p<0.001) and remarkably 
was over 30% of the continuous TGF-β1 stimulated hydrogels. 
 
TGF-β1 Adsorbed Peptide Hydrogels Stimulate Chondrogenesis 
Since 4 days of TGF-β1 supplementation stimulated BMSC chondrogenesis in 
peptide hydrogels, TGF-β1 was nonspecifically adsorbed onto KLD-peptide monomers 
(Ads-KLD) to determine if this method of delivery would provide sufficient pro-
chondrogenic stimulus. When foal equine BMSCs were encapsulated in Ads-KLD and 
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cultured in TGF-β1-free medium, DNA content was 50% higher than TGF-β-free 
controls by day 7 (Fig. 4.3A, p<0.001) and was statistically equivalent to hydrogels with 
medium-delivered TGF-β1. No further increase in DNA content after day 7 was seen for 
Ads-KLD cultured BMSCs resulting in 60% lower DNA content for Ads-KLD than for 
medium-delivered TGF-β1 at day 21 (p<0.001). Ads-KLD cultured BMSCs accumulated 
equivalent sGAG to medium-delivered TGF-β1 throughout the entire 21 day culture 
period (Fig. 4.3B) with a final sGAG content that was 25-fold higher than TGF-β1-free 
controls (p<0.001). Consistent with sGAG content, proteoglycan biosynthesis in Ads-
KLD was either higher or equivalent to hydrogels cultured with medium-delivered TGF-
β1 through 21 days (Fig. 4.3C) and was 4-fold higher than the TGF-β1-free control at day 
21 (p<0.001). In addition, the sGAG retained within the hydrogel as a percentage of the 
total produced (including sGAG lost to the conditioned medium) was 65% and 60% for 
BMSCs cultured in Ads-KLD and medium-delivered TGF-β1, respectively, at day 7 
(difference was not significant), and remained constant over 21 days in culture (Fig. 
4.3D). 
The solid matrix as a percentage of the total wet mass for BMSCs in Ads-KLD 
was equivalent to hydrogels with medium-delivered TGF-β1 at days 7 and 14 (Fig. 4.3E), 
while by day 21 the Ads-KLD encapsulated BMSCs had produced 25% less solid matrix 
than hydrogels with medium-delivered TGF-β1 (p<0.05). However, Ads-KLD BMSCs 
still had more than 2-fold higher percentage solid than TGF-β1-free controls (p<0.001). 
Protein biosynthesis showed that Ads-KLD cultured BMSCs were equivalent to culture 
with medium-delivered TGF-β1 at day 7 (Fig. 4.3F), but dropped to 50% of medium-
delivered TGF-β1 at days 14 and 21 (p<0.001). Ads-KLD encapsulated BMSCs still had 
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more than 2-fold higher protein biosynthesis than TGF-β1-free controls at day 21 
(p<0.01). 
 
Controlled Delivery of TGF-β1 with Peptide Hydrogels 
125I-labeled TGF-β1 was adsorbed onto KLD peptide monomers prior to self-
assembly or adsorbed onto molten agarose prior to gelation (TGF-β1 loaded within the 
hydrogel) without cells. Independent experiments showed that the uptake ratio (ratio of 
TGF-β1 concentration in the gel to concentration in the bath) of TGF-β1 did not decrease 
after 2 days of diffusion out of the adsorbed hydrogels indicating that 2 days was 
sufficient for the system to reach equilibrium (data not shown). Bath changes were thus 
conducted every 2-3 days and TGF-β1-loaded hydrogels were incubated at 37°C in a 
TGF-β1-free bath for 21 days. Collected bath samples were analyzed for 125I-TGF-β1 
content (Fig. 4.4A). By day 3, 16% of the total 125I-TGF-β1 loaded was washed out from 
KLD-peptide hydrogels, while nearly 40% was washed out from agarose hydrogels. By 
the end of 21 days, TGF-β1 washout had increased to 35% for KLD-peptide and nearly 
60% for agarose (Figs. 4.4A, 4.4B, p<0.001). At day 21, hydrogels were melted at 70°C 
and mechanically disrupted to measure retained 125I-TGF-β1.  KLD peptide retained 
nearly 50% of the total 125I-TGF-β1 loaded versus 14% for agarose hydrogels (Fig. 4.2B, 
p<0.001).  
To determine the effect of TGF-β1 delivery method on hydrogel adsorption, 125I-
TGF-β1 was added to either the bath or the hydrogel itself (TGF-β1 loaded in bath and 
gel, respectively) and incubated with agitation at 37°C for 5 days without bath changes. 
The uptake ratio of 125I-TGF-β1 (ratio of 125I-TGF-β1 concentration in the gel to the bath) 
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was 5-fold higher for KLD-peptide than for agarose hydrogels (Fig. 4.4C, p<0.001). In 
addition, for both KLD peptide and agarose, the uptake ratio was more than 2-fold higher 
when 125I-TGF-β1 was loaded in the gel rather than in the bath (p<0.001). Also, in both 
KLD peptide and agarose the uptake ratio of bath loaded 125I-TGF-β1 was still greater 
than one (18.5 ± 1.3 and 2.9 ± 0.2, respectively, mean ± sem). When excess unlabeled 
TGF-β1 (100 ng/mL) was added to hydrogel-loaded 125I-TGF-β1 KLD peptide and 
agarose, the uptake ratio decreased by 16% and 27%, respectively (Fig. 4.4D, p<0.001), 
and in both cases remained greater than one (72.2 ± 1.3 and 12.5 ± 0.2 for KLD and 
agarose, respectively). 
 
TGF-β1-adsorbed Hydrogels Produce Full-Length Aggrecan 
Bovine BMSCs encapsulated in both Ads-KLD and TGF-β1-adsorbed agarose 
(Ads-Agarose) produced equivalent sGAG to medium-delivered TGF-β1 by day 7 (Figs. 
4.5A and 4.5B, respectively, p<0.001). By day 21, total sGAG produced in Ads-KLD and 
Ads-Agarose was 40% of medium-delivered TGF-β1 (p<0.001), but was 6-fold and 3-
fold higher than TGF-β1-free controls, respectively (p<0.001). To further characterize the 
BMSC chondrogenic phenotype, proteoglycans were extracted from KLD-peptide and 
agarose samples and analyzed by Western blotting with an anti-G1 aggrecan antibody. 
With both adsorbed and medium-delivered TGF-β1, a large macromolecular species was 
identified running at the molecular weight of full-length aggrecan in KLD peptide and 
agarose (Fig. 4.5C). In KLD peptide, full-length aggrecan was the predominant species 
detected, consistent with the virtual absence of aggrecanase activity in peptide hydrogels 
(Chapter 2). In agarose with medium-delivered TGF-β1, a doublet band near 65 kDa was 
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the major immunoreactive band detected. However, in Ads-agarose the intensity of this 
doublet band was decreased and full-length aggrecan was the major product observed. 
This is consistent with a reduced level of aggrecanase activity when TGF-β1 was 
adsorbed to agarose hydrogels as compared to medium-delivered TGF-β1.  
 
KLD Peptide Adsorbed TGF-β1 Signals via SMAD2/3 
A 50-60 kDa species was detected via anti-Smad2/3 Western blotting in all 
samples after one day of culture (Fig. 4.6A). In samples encapsulated in Ads-KLD or 
treated with medium-delivered TGF-β1, pSmad2/3 was also detected at day 1. In addition, 
for a subset of animal donors (animal #2 in Fig. 4.4.6A) pSmad2/3 was detected in Teth-
KLD hydrogels. pSmad2/3 was detected throughout 21 days of culture in peptide 
hydrogels cultured in TGF-β1 supplemented medium and through day 4 of culture in 
Ads-KLD samples (Fig. 4.6B). Total Smad2/3 was detected in all samples through day 21, 
however it was more abundant for Ads-KLD samples than any other condition from day 
4-14 (Fig. 4.6B), making it a poor loading control. Semi-quantitative band densitometry 
showed statistically equivalent pSmad2/3 signaling for Ads-KLD and medium-delivered 
TGF-β1 samples at days 1 and 4, with Ads-KLD pSmad2/3 dropping to levels 
comparable to TGF-β1-free controls from day 14-21. For total Smad2/3, 2-factor 
ANOVA (for TGF condition and time) confirmed a significant trend with TGF condition 
(p<0.05), but not time, although no pairwise comparisons were significant. 
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4.4 Discussion 
TGF-β1 adsorbed to KLD peptide hydrogels (Ads-KLD) stimulated 
chondrogenesis of encapsulated BMSCs, inducing cell proliferation and producing a 
cartilage-like ECM that was similar to hydrogels stimulated by medium-delivered TGF-
β1. Delivery of an equivalent amount of TGF-β1 by an alternate method, tethering the 
growth factor to the KLD peptide via a biotin-streptavidin linkage (Teth-KLD), did not 
stimulate any marker for chondrogenesis above TGF-β1-free controls. Robust efficacy of 
Ads-KLD was demonstrated by the capacity to induce chondrogenesis of BMSCs 
isolated from two different species, equine and bovine, resulting in significant increases 
in hydrogel sGAG production over BMSCs cultured in TGF-β1-free conditions. In 
addition, equine BMSCs encapsulated in Ads-KLD produced neotissue with statistically 
equivalent cartilage ECM content and biosynthesis to KLD-encapsulated BMSCs 
stimulated by medium-delivered TGF-β1. 
TGF-β1 encapsulation in both acellular KLD-peptide and agarose hydrogels 
resulted in TGF-β1 adsorption and retention in both hydrogels for 21 days. Uptake ratio 
experiments confirmed higher TGF-β1 affinity for KLD peptide than for agarose, and 
showed that TGF-β1 uptake was higher when it was mixed with peptide solutions prior to 
gel assembly than when diffusing into the assembled peptide hydrogel from the bath. 
These experiments demonstrate the capacity of TGF-β1 to adsorb to two very different 
biomaterials, and a specific interaction between TGF-β1 and KLD peptide that was not 
present with agarose. TGF-β1 has been adsorbed to a wide range of materials including 
titanium fiber94, collagen-coated and uncoated titanium alloys99, and acidic gelatin108,109, 
which is consistent with our results showing TGF-β1 adsorption to both uncharged 
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agarose hydrogels and amphiphilic, zwitterionic KLD-peptide hydrogels. Given that the 
pore size of 2% low-melting-point (hydroxyethylated) agarose is approximately 35 nm110 
and the dimensions of TGF-β1 are less than 6 nm111, while in KLD peptide individual 
node-to-node fiber lengths have been measured at 370nm112, the higher TGF-β1 affinity 
for KLD peptide than agarose hydrogels is not likely to be due to restricted diffusion113. It 
may be related to the presence of negatively-charged aspartic acid residues in KLD 
peptide since basic TGF-β1 (pI=9.5)108 has been shown to interact electrostatically with 
acidic gelatin108,109. In addition, electrostatic interactions determine the release of small 
dye molecules from self-assembling peptides113,114, and these peptides have been shown 
to bind numerous growth factors including PDGF-BB, VEGF-A, bFGF, and 
angiopoietin-1 likely through non-covalent adsorption to the peptide nanofibers86,113. 
TGF-β1 uptake experiments also demonstrated that its affinity for KLD peptide 
depends on whether the peptide is in solution or assembled into an insoluble hydrogel 
(Fig. 4.4C). The dependence of the TGF-β1 interaction with KLD peptide on assembly 
may also involve electrostatic interactions. Since the assembled KLD peptide (pI=6.25, 
assuming pKa of each amino acid in the peptide is equal to the corresponding individual 
amino acid pKa as reported in Stryer Biochemistry115) has minimal net negative charge (-
0.1) at neutral pH, most electrostatic charges are likely shielded by adjacent peptides in 
the assembled gel. Thus when TGF-β1 is added to KLD peptide solution prior to 
assembly, it may have an increased capacity to adsorb than when TGF-β1 is added to the 
physiologically buffered bath and diffuses into the assembled peptide hydrogel. 
Chondrogenesis of BMSCs was shown to require TGF-β1 stimulation for just the 
initial 4 days of culture in peptide hydrogels. This may be due in part to the capacity of 
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KLD peptide to uptake TGF-β1 from the bath and thereby sustain TGF-β1 stimulation 
beyond the initial 4 days. Our results are consistent with a recent report where transient 
exposure to TGF-β1 for 2 weeks was shown to enhance the biomechanical and 
biochemical properties of chondrocyte-seeded agarose hydrogels116 over medium-
delivered TGF-β1 stimulation. Similarly, 3 weeks of transient TGF-β1 stimulation for 
BMSC-seeded agarose has been shown to produce equivalent cartilage-like biochemical 
properties to medium-delivered TGF-β1 stimulation117. 
Aggrecan Western analysis confirmed that full-length aggrecan was produced by 
Ads-KLD stimulated BMSCs, comparable to medium-delivered TGF-β1 stimulation of 
KLD encapsulated BMSCs and consistent with a recent report (Chapter 2). In agarose 
hydrogels stimulated by medium-delivered TGF-β1, the major immunoreactive product 
detected was a doublet band near 65 kDa consistent with the aggrecanase generated 
NITEGE neoepitope61. Consistent with these results, TGF-β1 has been shown to induce 
accumulation of aggrecan cleavage products in chondrocyte-seeded agarose92 and in 
BMSC-seeded agarose hydrogels (Chapter 2). In contrast with medium-delivered TGF-β1, 
agarose hydrogels with adsorbed TGF-β1 stimulated the production of predominantly 
full-length aggrecan with reduced accumulation of aggrecan cleavage products (Fig. 
4.5C). Clarke et al. has recently shown that cells sense TGF-β1 dose by depleting it 
through constitutive receptor trafficking processes118.  In addition, tumor cells with 
impaired receptor trafficking led to TGF-β1 overproduction, which correlated with a poor 
disease prognosis. Thus, TGF-β1 dose and signaling duration can have a significant 
impact on cell decisions and function, suggesting that adsorbed TGF-β1, which would be 
expected to signal for an initial period and then deplete, may stimulate chondrogenesis. In 
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contrast, medium-delivered TGF-β1 may provide a sustained signal that potentially 
upregulates aggrecan catabolism in addition to chondrogenesis. Analysis of Smad 2/3 
phosphorylation supported this idea of unique signaling paradigms for adsorbed and 
medium-delivered TGF-β1, with transient signaling for adsorbed TGF-β1, dissipating 
after one week, and sustained signaling for medium-delivered TGF-β1, with pSmad 2/3 
levels steady for the first week and trending higher in weeks 2-3 (Fig. 4.6C). 
Tethered TGF-β1 did not stimulate accumulation of a cartilage-like ECM or 
induce proliferation of BMSCs encapsulated in peptide hydrogels. This is in contrast to 
recent reports where covalently-tethered TGF-β1 stimulation induced myofibroblast 
differentiation119, increased matrix production of vascular smooth muscle cells120, and 
initiated cartilage-like ECM production in a magnetic-bead pellet culture system96. In 
addition, biotin-streptavidin sandwich tethered IGF-I in self-assembling peptide 
hydrogels improved cell survival and function after experimentally-induced myocardial 
infarction in a rat model20. It was thus surprising that tethered KLD in the current study 
was an ineffective chondrogenic stimulus. Potential explanations include improper 
presentation of the tethered TGF-β1 ligand to the cell surface preventing receptor binding, 
blocked ligand internalization by the high-affinity biotin-streptavidin linkage leading to 
altered intracellular signaling, and steric interference between the ligand and cell surface 
receptor generated by newly secreted matrix proteins shutting down signaling 
prematurely. Phosphorylation of Smad 2/3 by teth-KLD encapsulated BMSCs at day 1 
for a subset of samples (Fig. 4.6A) suggests that tethered TGF-β1 can generate 
intracellular signal and that further optimization of the TGF-β tethering technology may 
enable effective chondrogenic stimulation, potentially through increasing TGF-β1 dose. 
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 4.5 Summary 
Adsorption of TGF-β1 to KLD peptide and agarose hydrogels stimulated 
chondrogenesis of BMSCs isolated from both bovine and equine sources. KLD peptide 
had significantly higher TGF-β1 uptake and retained significantly more TGF-β1 during 
wash out experiments than agarose hydrogels. Introducing unlabeled TGF-β1 at two 
orders of magnitude higher concentration than radiolabeled TGF-β1 had a minor impact 
on uptake. Adsorbed TGF-β1 stimulated the production of full length aggrecan by 
BMSCs in both KLD peptide and agarose hydrogels, while medium-delivered TGF-β1 
stimulated aggrecan cleavage product formation in agarose hydrogels, potentially due to 
differences in Smad 2/3 phosphorylation. Given the wide diversity cell functions 
controlled by TGF-β1 signaling101,102 and the importance of TGF-β1 signal duration and 
depletion kinetics in determining outcome118, tuning the delivery duration and dose for 
pro-chondrogenic growth factors will likely be critical to the success of BMSC-based 
cartilage resurfacing technologies. 
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4.7 Tables 
Table 4.1 Percent sGAG Retained 
(† vs. TGF) 
KLD Agarose  Day 7 Day 14 Day 21 Day 7 Day 14 Day 21
TGF 59±1 58±1† 58±1† 56±2 50±2 41±1 
Ads-KLD 52±2 44±1† 30±1† 55±1 45±1 39±2+
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Figure 4.1 TGF-β1 tethered to KLD hydrogels (Teth-KLD); DNA and sGAG content 
Bovine BMSCs encapsulated in Teth-KLD or unmodified KLD peptide hydrogels and cultured 
in TGF-β1-free medium (Cntl), or continuous TGF-β1 supplemented medium (TGF). (A) DNA 
Content. (B) sGAG Content. Stats: mean ± sem, n=4; * vs. Cntl; # vs. Teth-KLD; p<0.001. 
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Figure 4.2 TGF-β1 takeaway DNA content, sGAG content, and ECM biosynthesis 
Adult equine BMSCs encapsulated in KLD peptide hydrogel and cultured for 21 days in TGF-
β1-free medium (Cntl), 4, 7, or 14 days of TGF-β1 supplemented medium followed by TGF-β1-
free medium (4D, 7D, or 14D, respectively), and continuous TGF-β1 supplemented medium 
(TGF). (A) DNA Content. (B) sGAG Content. (C) Protein Biosynthesis. (D) Proteoglycan 
Biosynthesis. Stats: mean ± sem, n=8 (4 gels x 2 animals); * vs. Cntl; † vs. TGF; p<0.01. 
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Figure 4.3 TGF-β1 adsorbed to KLD hydrogels (Ads-KLD); DNA content, sGAG content, 
and ECM biosynthesis 
Young equine BMSCs encapsulated in Ads-KLD or unmodified KLD peptide hydrogels and 
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cultured in TGF-β1-free medium (Cntl), or continuous TGF-β1 supplemented medium (TGF). 
(A) DNA Content. (B) sGAG Content. (C) Proteoglycan Biosynthesis. (D) Percent sGAG 
retained in hydrogels vs. total produced (including sGAG lost to conditioned medium). (E) 
Percent solid matrix, dry weight vs. wet weight. (F) Protein Biosynthesis. Stats: mean ± sem, 
n=8 (4 gels x 2 animals); * vs. Cntl; † vs. TGF; p<0.05. 
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Figure 4.4 TGF-β1 adsorption to acellular KLD and agarose hydrogels 
(A) Cumulative 125I-TGF-β1 washout with bath changes after encapsulation in KLD or agarose 
hydrogels. Each datapoint corresponds to a complete bath change. (B) 125I-TGF-β1 distribution 
in samples after 21-day washout shown in (A). (C) Uptake ratio of 125I-TGF-β1 for KLD peptide 
and agarose hydrogels scaffolds when 125I-TGF-β1 was encapsulated within the gel prior to gel 
casting (Load TGF in Gel) or when it diffused in from the bath after gel casting (Load TGF in 
Bath). (D) Uptake ratio of 125I-TGF-β1 when encapsulated with 0, 10, or 100 ng/mL of 
unlabeled TGF-β1 within KLD peptide or agarose hydrogels. Stats: mean ± sem, n=6 (A,B,C), 
n=4 (D); * vs. KLD without unlabeled-TGF-β1; † vs. agarose without unlabeled-TGF-β1; ‡ vs. 
Load TGF in Gel; p<0.001. 
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Figure 4.5 sGAG production in TGF-β1 adsorbed KLD peptide and agarose hydrogels 
Total sGAG production by bovine BMSCs encapsulated in TGF-β1 adsorbed (A) KLD peptide 
(Ads-KLD) or (B) agarose (Ads-Agarose) or cultured in corresponding unmodified hydrogels 
with TGF-β1-free medium (Cntl) or continuous TGF-β1 supplemented medium (TGF). (C) 
Anti-G1 domain aggrecan western blot of proteoglycans extracted from Ads-KLD, Ads-Agarose, 
and corresponding Cntl and TGF hydrogels. Stats: mean ± sem, n=4; * vs. Cntl; † vs. TGF; 
p<0.001. 
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Figure 4.6 Smad 2/3 phosphorylation for bovine BMSCs encapsulated in KLD peptide 
hydrogels  
BMSCs were stimulated by adsorbed, tethered, or medium-delivered TGF-β1 (Ads-KLD, Teth-
KLD, or TGF, respectively) or cultured in TGF-β1-free medium (Cntl). (A) Day 1 western 
blots for pSmad 2/3, Smad 2/3, and β1-actin from two different BMSC donors. (B) Day 4-21 
western blots for animal #1. (C) Semi-quantification of Smad 2/3 phosphorylation by band 
densitometry. Stats: mean ± sem, n=3; * vs. Cntl; † vs. TGF; p<0.05. 
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Chapter 5. Summary and Conclusions 
A technique for encapsulation of bone marrow stromal cells (BMSCs) within self-
assembling peptide hydrogels and inducing chondrogenic differentiation has been 
developed (Chapter 2, Appendix C). Encapsulating BMSCs within peptide hydrogels 
enhanced ECM production, cell proliferation, and reduced aggrecan catabolism compared 
to BMSC chondrogenesis in agarose hydrogels. Given that chondrocyte-seeded tissue 
engineering strategies are established in clinical practice for cartilage repair (Chapter 1), 
neotissue forming capacity BMSC-seeded peptide hydrogels was compared to that for 
chondrocytes from both young and adult donors (Chapter 3). Young chondrocytes 
produced neotissue with the highest sGAG content, which is consistent with expectation 
for cells isolated from cartilage that is still developing and actively remodeling.  However, 
young chondrocytes were not compatible with the goal of delivering an autologous-cell 
seeded therapy to adult patients in a single surgical procedure. Thus, it was a significant 
finding that ECM production of adult BMSCs was superior to adult chondrocytes and 
that the dynamic mechanical properties of adult BMSC-seeded neotissue exceeded those 
of even young chondrocytes. 
Neotissue production by BMSCs is dependent upon chondrogenic differentiation, 
which must be induced by the addition of bioactive factors. For in vitro work, the culture 
medium has commonly been supplemented with transforming growth factor β1 (TGF-β1) 
and dexamethasone to stimulate chondrogenesis16. However, for in vivo applications cost 
of repeated dosing and undesirable systemic effects of potent prochondrogenic growth 
factors motivate the need for local, controlled release. A technology for adsorbing TGF-
β1 to self-assembling peptide hydrogels was designed (Chapter 4), which retained TGF-
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β1 within the peptide for up to 21 days and stimulated neotissue production comparable 
to medium-delivered TGF-β1. 
One technical challenge of note is the sensitivity of BMSCs to soluble self-
assembling peptide solutions. These solutions are inherently at low pH and BMSCs must 
be mixed with the viscous peptide solution and injected into the casting and assembly 
mold rapidly to maintain viability (60 seconds is a good maximum BMSC exposure to 
soluble peptide before assembly). Exceeding this time will likely cause cell death and 
inconsistent chondrogenesis for the surviving population. Two other factors that may be a 
source of variability in neotissue production are cell seeding density and peptide 
concentration. Both present technical challenges; cell seeding density because a 
miniscule fraction of the total cell population was counted by hand with a hemocytometry 
slide and peptide concentration because the mass of peptide was close to the lower 
sensitivity limit of the mass balance used. Given that cell-cell contact, cell-peptide 
adhesion, and hydrogel contraction were proposed to be central to enhanced 
chondrogenesis in peptide hydrogels (Chapter 2), variations in cell seeding density and 
peptide concentration may dramatically impact the nature of neotissue produced. 
Potentially related is the variation in uptake ratio at equilibrium for acellular peptide 
hydrogels (Figure 4.4). If peptide concentration is variable and responsible for the 
differences, it may suggest that different doses of TGF-β1 may have been administered in 
each experiment, contributing to variable ECM production.  
The virtual absence of chondrogenesis in BMSCs seeded in TGF-β1 tethered 
peptide hydrogels was surprising and potentially should not be interpreted as a conclusive 
failure of this technology. Smad 2/3 analysis provided a glimmer of hope by showing 
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phosphorylation after one day in culture in a subset of samples (Figure 4.6). Looking at 
Smad 2/3 phosphorylation at multiple timepoints within the first 24 hours of culture may 
clarify the capacity for tethered TGF-β1 to signal. An additional potential complicating 
factor is the possibility that the high-affinity bond in the tether system changes the 
availability of TGF-β1 to signaling such that a higher dose may be needed than in the 
adsorbed case. For example, TGF-β1 trapped within peptide fibers during self-assembly 
may diffuse out when nonspecifically adsorbed but not when biotin-streptavidin tethered. 
Increasing the dose of tethered TGF-β1 may thus be necessary to generate sufficient 
bioavailability.  
Another related question is whether TGF-β1 stimulates BMSC-mediated 
breakdown of the peptide scaffold. If so it may be that cells can access additional TGF-β1 
stores as they degrade, remodel, and replace the peptide with newly secreted ECM. This 
is of particular interest in the adsorbed TGF-β1 system where 50% of the dose is retained 
in acellular peptide hydrogels after 21 days in washout experiments (Figure 4.4). A 
simple test of this hypothesis would be to culture BMSCs with 125I-TGF-β1 adsorbed 
peptide hydrogels and measure radiolabel retention within the neotissue. BMSC-mediated 
remodeling would likely release any 125I-TGF-β1 stores by day 21, in contrast to the 
acellular experiment. 
The in vitro model system developed in this work is well suited to developing an 
understanding of neotissue formation sensitivity to all of the above mentioned parameters. 
However, successful cartilage repair in the clinic will require testing in animal models 
and human subjects with the goals of achieving durable cartilage repair, native 
physiological function, and stable integration with surrounding cartilage. The work in this 
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thesis provides a foundation for designing these in vivo studies. With the capacity to 
enhance chondrogenesis of BMSCs, reduce aggrecan catabolic activity, and deliver 
prochondrogenic factors, self-assembling peptide hydrogels are a promising candidate 
technology for cartilage repair and regeneration. 
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Appendix A. Chondrogenesis of BMSCs Genetically Modified to 
Express TGF-β1 
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Figure A.1 Chondrogenesis of ads-TGF-β1 transfected bovine BMSCs encapsulated in 
peptide hydrogels 
BMSCs transfected with 7000 adenoviral particles/cell of GFP or TGF-β1 vector (aGFP or 
aTGF, respectively). aGFP hydrogels were cultured with or without medium-delivered 
recombinant human TGF-β1 (rTGF or  Cntl, respectively). (A) DNA Content, (B) sGAG 
Content, (C) Protein Biosynthesis, (D) Proteoglycan Biosynthesis. 
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Appendix B. BMSC Isolation from Bovine Tissue 
Adapted from protocols developed by J Connelly, J Mouw, P Kopesky, and J Kisiday 
 
Supplies 
Bovine stifle joint (Research 87, Marlborough, MA) 
 
Bone Marrow Harvest and Processing 
1. Prepare 1x50mL conical with 25 mL PBS+PSA for each bone to be harvested 
2. Remove all connective tissue and muscle around mid-diaphysus of each bone 
3. Clean bone with 70% ethanol 
4. Cut the bone with a sterilized hand-saw blade and transfer to the tissue culture hood 
5. Carefully removed bone marrow with a forceps and small scoop and transfer to 
50mL conical tubes with PBS.  Avoid scraping the interior surface of the bone 
6. Break up bone marrow by vigorous pipetting with a 25mL followed by 5mL pipette. 
May also need to use a syringe without a needle attached to apply enough pressure 
7. Continue to homogenize bone marrow by passing the material through a 16 gauge 
needle 
8. Centrifuge homogenized bone marrow 1000x g for 15 minutes 
9. Carefully aspirate supernatant and the fatty layer 
10. Resuspend in fresh PBS, pass material through an 18 gauge needle and then through 
a 70 µm cell strainer 
 
Nucleated Cell Count and Cell Plating 
1. Dilute cell suspension in Ammonium Chloride-Tris Base (7.6mg/mL AmCl, 
2.4mg/mL Tris Base) (** JC suggested 1:1 dilution in 4% acetic acid); 1:20 dilution 
in AmCl/Tris for nucleated cell count via Trypan Blue (** Dilutions may need to be 
adjusted for each harvest.) 
2. Obtain approximate nucleated cell count 
3. Centrifuge cell suspension at 200 x g for 15 min 
4. Aspirate supernatant and add low glucose DMEM + 10% ES-FBS, PSA, HEPES, & 
1ng/mL b-FGF 
5. Pre-plate approximately 75x106 cells in 5mL on 100mm tissue culture treated petri 
dishes 
6. Incubate for 30 min to allow rapidly adhering cells to attach 
7. Transfer media and non-adherent cells to a T-flask and add another 10mL expansion 
medium (approximately 1x106 cells/cm2 in 15 mL media; ~75x106/T-75) 
8. After 2 days in culture, remove expansion media and add fresh expansion medium 
9. Continue to culture flasks until cells are nearly (75-80%) confluent [P0] 
10. Remove cells with 0.05% trypsin-EDTA, centrifuge and resuspend in PBS, and 
count via Trypan Blue 
11. Either freeze in 5 million cells/vial aliquots or re-plate at approximately 6,000/cm2 
12. Culture until 60%-70% confluent (2-3 days), passage [P1], and reseed again at 
6,000/cm2 
13. Culture again until 60%-70% confluent (2-3 days), passage [P2], and seed into 3-D 
constructs for chondrogenesis 
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Appendix C. BMSC Encapsulation in Self-Assembling Peptide 
Hydrogels 
Supplies 
Custom 3-piece casting mold (Ring, Cap, Post) 
2% LMP Agarose (Invitrogen) 
1.25 mL sterile individually wrapped repeater pipette tips 
24-well non-tissue culture treated plates 
1X PBS without Ca2+ or Mg2+, sterile, pH=7.2 
 
Cast Acellular Agarose Rings (1-2 days prior to BMSC trypsinization) 
1. Sterilize 2% agarose by autoclaving on the wet cycle for 20 min. 
2. Place 2% agarose in 65°C water bath 
3. Assemble 3-piece casting frames in each well of a 24-well plate in the following 
order: ring, cap, post. Make sure smooth side of ring and cap are touching. Use sterile 
forceps and spatula to position frames. See Figure 2.1 
4. Assemble repeater pipette (old model) with 1.25 mL tip and set to 125 µL 
5. Remove agarose from the water bath and place in the hood on styrofoam 
6. Draw agarose into repeater pipette and inject into frames 
7. Once all 24 wells are filled with agarose, cover plate and place at 4°C for 5 min. Be 
careful not to leave in hood too long or frame disassembly will be difficult 
8. Return plate to hood and gently remove the frames in reverse order: post, cap, ring. 
9. Add ~0.5mL 1X PBS to all wells 
10. Store at 4°C for up to 4 days 
 
Supplies 
Casting medium: 25mM HEPES, with hgDMEM, ITS+1, NEAA, Na Pyr, Proline, PSA 
Culture medium: 10mM HEPES, with hgDMEM, ITS+1, NEAA, Na Pyr, Proline, PSA 
FBS medium: lgDMEM, 10% ES-FBS (Invitrogen), 10mM HEPES, PSA 
1X PBS, sterile, pH=7.2 
0.05% Trypsin/EDTA 
10% Sucrose, Sterile 
10% Sucrose, Sterile w/2.5mM HEPES 
Peptide powder, sterile, (e.g. for 0.35% KLD12, 1.5mL x 3.5mg/mL x 1.2 = 6.3 mg/cast) 
2mL screw top tubes, sterile 
5mL polypropylene snap top tubes, sterile (BD Falcon) 
1.0 or 1.25 mL sterile individually wrapped repeater pipette tips 
 
Cast BMSC-seeded Self-Assembling Peptide Hydrogels (2 person procedure) 
1. Aspirate PBS from each agarose ring and clean up loose agarose debris 
2. Add ~0.5mL casting medium (above) to each well 
3. Place plate(s) in 37°C incubator 
4. Dissolve peptide at 4.375 mg/mL (for 3.5mg/mL final concentration) in sterile 10% 
sucrose by vortexing & sonicating. Leave peptide solution in sonicator. 
5. Trypsinize cells and inactivate with FBS medium 
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6. Centrifuge cells and resuspend in FBS medium at >10x106 cells/mL (guess at count 
based on previous passage yield) 
7. Count & aliquot 15x106 cells into 2mL sterile screw top tubes. Store tubes at 4°C. 
8. Prepare 5mL tubes with 1.2mL of 4.375 mg/mL peptide solution; return to sonicator 
9. Spin 2mL tube with 15x106 cells at 100 x g for 5 min 
10. While spinning, aspirate 23 acellular agarose rings so that the center well is dry 
11. Assemble repeater pipette with 1.0 mL or 1.25 mL tip and set to 50 µL 
12. Person #1 aspirate medium from cells and resuspend in 300 µL of 10% sucrose + 2.5 
mM HEPES 
13. Person #2 hold 5mL tube with 1.2mL peptide solution 
14. Person #1 inject cell suspension into 5mL tube 
15. Starting from the time the cells are added to the peptide complete the following in 60 
seconds: Gently vortex to ensure homogeneous cell distribution in peptide solution; 
gently draw cell-peptide suspension into repeater pipette, avoiding bubbles; rapidly 
but gently dispense 50 µL into the center well of up to 23 agarose rings 
16. Wait at least 5 min and add 300 µL of casting medium to each plug to cover the top 
17. Change medium replacing casting medium with culture medium 
18. Place plate in incubator 
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Appendix D. Aggrecan Extraction and Purification 
Adapted from protocols developed by J Sandy and Anna Plaas  
 
Materials: 
Guanidine HCl (4M) 
Sodium Acetate (100mM) 
Protease Complete Tablets (Roche, Cat #11 697 498 001) 
 
1. Make desired volume of 4M Guanidine HCl in 100mM Sodium Acetate buffer and 
adjust pH to ~7.2.  Rough guide: For tissue engineered plugs, make 1mL for every 
~40mg of tissue wet weight with sGAG content of ~120ug (i.e. plug sGAG content is 
~3ug/mg wet weight). I would double the amount of extraction solution if using 
native tissue instead of engineered samples. 
2. Add appropriate fraction of protease complete tablet per manufacturer’s instructions. 
(Inhibits a broad range of proteases). 
3. Mechanically disrupt sample.  May use a scalpel to dice (works for tissue engineered 
plugs).  If using native cartilage tissue, may want to pulverize and homogenize. 
4. Add appropriate volume of combined solution samples as per step #1 above. 
5. Mix on shaker at 4C for 48hrs (probably excessive, but will maximize PG extraction) 
6. Spin for 0.5-1hr at ~16,000 x g in microcentrifuge at 4C. 
7. Transfer clarified supernatant to new tube and discard pellet. 
8. Add CsCl powder until solution density is 1.58g/mL.  Check density by weighing a 
known volume of solution. 
9. Transfer sample to an appropriate tube for ultracentrifuge and balance ultracentrifuge 
rotor exactly! 
10. Spin as long and as hard as you can. 72hrs at ~500,000 x g should produce a good 
density gradient. 
11. Immediately at the end of the spin, carefully pipette fractions of the sample.  Splitting 
1mL into ~10 x 100uL fractions works well. Start by pipetting off the very top and 
working down the tube. Be aware that a hard pellet of CsCl may form at the bottom; 
the density gradient will likely still be sufficient for PG purification. 
12. Measure the density of the fractions as in step #8. 
13. Combine fractions based on density. D1>1.54g/mL; 1.46g/mL<D2<1.54g/mL82  
14. Dialyze with 500 volumes of 1M NaCl for 12-24 hrs. 
15. Dialyze with 500 volumes of MilliQ filtered, distilled H20. 
 
 106
Appendix E. Smad 2/3 Western Blot Analysis 
Supplies: 
NuPage 10% Bis-Tris Gel 1.5mm x 15 well; Invitrogen, Cat# NP0316BOX 
Stds (Novex Sharp Pre-Stained, store -20C, Cat# LC5800) 
Reducing Agent, NuPage, Invitrogen Cat# NP0004 (store 4C) 
Sample Buffer, NuPage, Invitrogen Cat# NP0007 (store RT)  
NuPage MOPS SDS Running Buffer, Invitrogen 
Transfer Buffer (3.03g Tris, 14.4g Glysine, 800mL aqueous vol, pH=8.3; 200mL 
Methanol) 
PVDF Membrane 
P-SMAD2 antibody, Cell Signaling, Cat# 3101 
Total SMAD2/3 antibody, Cell Signaling, Cat# 3102 
 
Run Gel and Western Blot: 
1. Max vol per lane = 25uL 
2. Make sample buffer mix 2uL reducing agent+5uL sample buffer per lane (make up 
one lane, 7uL, extra) 
3. Mix appropriate amount of protein from samples with 7uL of sample buffer 
4. Boil 5min 
5. Make 500 mL (800mL for 2 gels) MOPS running buffer by diluting 20X stock with 
DI H2O 
6. Assemble Gel apparatus, remove comb, fill inner chamber above white bar fill outer 
chamber with remaining buffer 
7. Run 150V, ~90 min, @RT until stds reach bottom of gel (can increase to 200V) 
8. While running, make transfer buffer (fresh each time) 
9. Cut PVDF membrane to size 
10. When gel is finished, activate PVDF membrane by wetting in 100% methanol (both 
sides) and rinsing in DI H2O.  
11. Place membrane in pan filled with transfer buffer. Also wet transfer apparatus in pan, 
black side down; stack sandwich in this order (item a on bottom, item f on top):  
a. sponge; b. blot paper; c. gel; d. membrane; e. blot paper; f. sponge 
12. Disassemble gel, break cassette with putty knife, cut off comb and base of gel (the 
thick part) 
13. Place gel in pan with transfer apparatus and allow to equilibrate for 10-15min 
14. Complete assembly of sandwich and use test tube to roll out air bubbles 
15. Insert sandwich into transfer chamber with ice block and stir bar. 
16. Transfer in 4C room at 75V for 60 min. 
17. Block 1 hr at RT in TBS + 0.1% Tween 20 + 5% BSA (SMAD2/3 antibody) (sonicate 
and filter this prior to use) or TBS-T + 5% milk (PSMAD2 antibody) 
18. Incubate with primary antibody + TBS-T + 5% BSA/milk at 4C overnight 
19. Wash 4x in TBS-T with 5 min between rinses (15 min total time) 
20. Incubate with secondary antibody (1:2000)+TBS-T+5% BSA/milk for 1 hr at RT 
21. Rinse 4x in TBS-T with 10 min between rinses (30 min total time) 
22. 1:1 mix of imaging components, ~5mL per membrane, 1 min on shaker at RT 
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